https://trial.medpath.com/news/tiziana-wins-funding-for-small-clinical-trial-in-als-of-intranasal-foralumab-als-news-today 2024-11-22T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiziana-wins-funding-for-small-clinical-trial-in-als-of-intranasal-foralumab-als-news-today 2024-11-22T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-sees-success-in-dual-emergency-engineered-tissue-trials-clinical-trials-arena 2024-11-22T14:55:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-sees-success-in-dual-emergency-engineered-tissue-trials-clinical-trials-arena 2024-11-22T14:55:05+00:00 weekly 0.7 https://trial.medpath.com/news/plus-therapeutics-to-present-positive-foresee-clinical-trial-summary-demonstrating-biospace 2024-11-22T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plus-therapeutics-to-present-positive-foresee-clinical-trial-summary-demonstrating-biospace 2024-11-22T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-s-penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-biospace 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-s-penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-biospace 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-fast-track-designations-to-gildeuretinol-for-stargardt 2024-11-22T14:38:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-fast-track-designations-to-gildeuretinol-for-stargardt 2024-11-22T14:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/how-an-aha-moment-sparked-a-breakthrough-for-car-t-in-lbcl-stat-news 2024-11-22T14:22:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-an-aha-moment-sparked-a-breakthrough-for-car-t-in-lbcl-stat-news 2024-11-22T14:22:35+00:00 weekly 0.7 https://trial.medpath.com/news/promising-steps-to-hiv-vaccine-trump-tariffs-threaten-chinese-profits-5-biotech-stories 2024-11-22T14:13:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-steps-to-hiv-vaccine-trump-tariffs-threaten-chinese-profits-5-biotech-stories 2024-11-22T14:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T14:01:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T14:01:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-pr-newswire 2024-11-22T14:00:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-pr-newswire 2024-11-22T14:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-systemic-treatment-for-initially-unresectable-colorectal-liver-metastases-jama-network 2024-11-22T13:57:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-systemic-treatment-for-initially-unresectable-colorectal-liver-metastases-jama-network 2024-11-22T13:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/enveda-therapeutics-gets-a-130m-boost-toward-eczema-treatment-autogpt 2024-11-22T13:42:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enveda-therapeutics-gets-a-130m-boost-toward-eczema-treatment-autogpt 2024-11-22T13:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-of-chelsea-s-wellbeing-initiative-a-research-practice-partnership-boston-college 2024-11-22T13:41:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-of-chelsea-s-wellbeing-initiative-a-research-practice-partnership-boston-college 2024-11-22T13:41:16+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:39:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/face-to-face-huntington-s-disease-families-are-heard-by-the-fda-hdbuzz 2024-11-22T13:33:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/face-to-face-huntington-s-disease-families-are-heard-by-the-fda-hdbuzz 2024-11-22T13:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-goal-met-in-phase-3-solar-recur-trial-urology-times 2024-11-22T13:29:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-goal-met-in-phase-3-solar-recur-trial-urology-times 2024-11-22T13:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/savara-to-present-phase-3-trial-results-for-breakthrough-apap-treatment-at-bts-meeting 2024-11-22T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-to-present-phase-3-trial-results-for-breakthrough-apap-treatment-at-bts-meeting 2024-11-22T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of 2024-11-22T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of 2024-11-22T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/non-alcoholic-steatohepatitis-nash-treatment-market-2032-clinical-trials-medication 2024-11-22T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-alcoholic-steatohepatitis-nash-treatment-market-2032-clinical-trials-medication 2024-11-22T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-pr-newswire 2024-11-22T13:06:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-pr-newswire 2024-11-22T13:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T13:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T13:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-secures-fda-nod-for-ziihera-to-treat-her2-positive-btc 2024-11-22T13:01:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-secures-fda-nod-for-ziihera-to-treat-her2-positive-btc 2024-11-22T13:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-fends-off-adcomm-s-safety-concerns-on-andexxa-axes-mid-stage-opioid 2024-11-22T12:42:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-fends-off-adcomm-s-safety-concerns-on-andexxa-axes-mid-stage-opioid 2024-11-22T12:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector 2024-11-22T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector 2024-11-22T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector-yahoo-finance 2024-11-22T12:36:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector-yahoo-finance 2024-11-22T12:36:33+00:00 weekly 0.7 https://trial.medpath.com/news/jiangsu-hansoh-adc-hs-20093-holds-potential-to-set-new-standard-in-sclc-second-line 2024-11-22T12:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jiangsu-hansoh-adc-hs-20093-holds-potential-to-set-new-standard-in-sclc-second-line 2024-11-22T12:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-researchers-uses-exome-sequencing-to-identify-individuals-at-risk-of 2024-11-22T12:34:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-researchers-uses-exome-sequencing-to-identify-individuals-at-risk-of 2024-11-22T12:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-agrees-on-pediatric-study-plan-with-fda-placera 2024-11-22T12:33:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-agrees-on-pediatric-study-plan-with-fda-placera 2024-11-22T12:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/global-cell-and-gene-therapy-trials-driving-innovation-in-oncology-and-beyond 2024-11-22T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-cell-and-gene-therapy-trials-driving-innovation-in-oncology-and-beyond 2024-11-22T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/news/hepa-air-purifiers-show-limited-impact-on-rsv-and-respiratory-infections-in-aged-care-facilities 2024-11-22T12:22:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hepa-air-purifiers-show-limited-impact-on-rsv-and-respiratory-infections-in-aged-care-facilities 2024-11-22T12:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/deprescribing-anticholinergics-to-preserve-brain-health-reducing-the-risk-of-dementia-trials 2024-11-22T11:35:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deprescribing-anticholinergics-to-preserve-brain-health-reducing-the-risk-of-dementia-trials 2024-11-22T11:35:16+00:00 weekly 0.7 https://trial.medpath.com/news/open-label-study-finds-aficamten-could-help-most-ohcm-patients-avoid-surgery 2024-11-22T11:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/open-label-study-finds-aficamten-could-help-most-ohcm-patients-avoid-surgery 2024-11-22T11:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-bispecific 2024-11-22T11:21:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-bispecific 2024-11-22T11:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/lipid-nanoparticle-mediated-mrna-delivery-to-cd34-cells-in-rhesus-monkeys-nature 2024-11-22T11:21:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipid-nanoparticle-mediated-mrna-delivery-to-cd34-cells-in-rhesus-monkeys-nature 2024-11-22T11:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/short-term-hormone-therapy-for-menopause-won-t-harm-women-s-brains 2024-11-22T11:05:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/short-term-hormone-therapy-for-menopause-won-t-harm-women-s-brains 2024-11-22T11:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/could-a-vitamin-be-effective-treatment-for-copd 2024-11-22T11:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-a-vitamin-be-effective-treatment-for-copd 2024-11-22T11:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-china-ltd-fruzaqla-r-launched-in-japan-by-takeda-research-tree 2024-11-22T10:44:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-china-ltd-fruzaqla-r-launched-in-japan-by-takeda-research-tree 2024-11-22T10:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r-multiple-myeloma-cgtlive-r 2024-11-22T10:42:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r-multiple-myeloma-cgtlive-r 2024-11-22T10:42:21+00:00 weekly 0.7 https://trial.medpath.com/news/research-assesses-feasibility-of-collaborative-clinical-trials-between-health-tech-providers 2024-11-22T10:41:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-assesses-feasibility-of-collaborative-clinical-trials-between-health-tech-providers 2024-11-22T10:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/claudin-18-2-targeted-therapy-market-forecast-clinical-globenewswire 2024-11-22T09:58:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/claudin-18-2-targeted-therapy-market-forecast-clinical-globenewswire 2024-11-22T09:58:23+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-multi-billion-dollar-keytruda-levels-up-with-novel-subcutaneous-delivery 2024-11-22T09:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-multi-billion-dollar-keytruda-levels-up-with-novel-subcutaneous-delivery 2024-11-22T09:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-s-fda-win-exenatide-approval-novel-migraine-autoinjector-resubmission-stock-titan 2024-11-22T09:51:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-s-fda-win-exenatide-approval-novel-migraine-autoinjector-resubmission-stock-titan 2024-11-22T09:51:25+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-receives-breakthrough-therapy-designation-for-rp1-globenewswire 2024-11-22T09:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-receives-breakthrough-therapy-designation-for-rp1-globenewswire 2024-11-22T09:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/uk-pioneers-point-of-care-manufacturing-framework-for-cell-therapies-with-2025-implementation-target 2024-11-22T08:41:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-pioneers-point-of-care-manufacturing-framework-for-cell-therapies-with-2025-implementation-target 2024-11-22T08:41:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-updates-fludarabine-phosphate-labeling-in-chronic-lymphocytic-leukemia 2024-11-22T08:26:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-updates-fludarabine-phosphate-labeling-in-chronic-lymphocytic-leukemia 2024-11-22T08:26:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-adt-in-hormone-sensitive-prostate-cancer 2024-11-22T08:26:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-adt-in-hormone-sensitive-prostate-cancer 2024-11-22T08:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-markets-insider 2024-11-22T08:18:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-markets-insider 2024-11-22T08:18:56+00:00 weekly 0.7 https://trial.medpath.com/news/improving-outcomes-using-ribociclib-in-high-risk-node-negative-breast-cancer 2024-11-22T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-outcomes-using-ribociclib-in-high-risk-node-negative-breast-cancer 2024-11-22T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/fgfr-altered-nmibc-treatment-advances-with-tar-210-findings-targeted-oncology 2024-11-22T08:15:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fgfr-altered-nmibc-treatment-advances-with-tar-210-findings-targeted-oncology 2024-11-22T08:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-with-adt-for-patients-with-mhspc-pharmacy-times 2024-11-22T07:38:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-with-adt-for-patients-with-mhspc-pharmacy-times 2024-11-22T07:38:33+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-a-patient-health-engagement-phe-model-on-rehabilitation-participation-in-patients-trials 2024-11-22T07:34:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-a-patient-health-engagement-phe-model-on-rehabilitation-participation-in-patients-trials 2024-11-22T07:34:28+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-22T07:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-22T07:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/updated-phase-2-oragrowth-data-presented-at-espe-2024-demonstrate-sustained-growth 2024-11-22T07:27:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-phase-2-oragrowth-data-presented-at-espe-2024-demonstrate-sustained-growth 2024-11-22T07:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T07:23:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T07:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-grant-aims-to-improve-research-and-trials-for-veterans-health-va-gov 2024-11-22T07:19:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-grant-aims-to-improve-research-and-trials-for-veterans-health-va-gov 2024-11-22T07:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/neuracle-genetics-ng101-receives-fda-fast-track-designation-and-completes-dosing-for 2024-11-22T06:40:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuracle-genetics-ng101-receives-fda-fast-track-designation-and-completes-dosing-for 2024-11-22T06:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-safety-data-show-switching-between-rituximab-biosimilars-does-not-increase 2024-11-22T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-safety-data-show-switching-between-rituximab-biosimilars-does-not-increase 2024-11-22T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/the-latest-in-clostridioides-difficile-research-and-news-contagion-live 2024-11-22T05:58:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-latest-in-clostridioides-difficile-research-and-news-contagion-live 2024-11-22T05:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T04:32:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T04:32:30+00:00 weekly 0.7 https://trial.medpath.com/news/trial-tests-focused-ultrasound-to-battle-melanoma-uva-health-newsroom 2024-11-22T04:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-tests-focused-ultrasound-to-battle-melanoma-uva-health-newsroom 2024-11-22T04:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-jazz-pharma-s-ziihera-to-treat-adults-with-previously-treated-unresectable 2024-11-22T04:31:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-jazz-pharma-s-ziihera-to-treat-adults-with-previously-treated-unresectable 2024-11-22T04:31:19+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-22T04:25:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-22T04:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/dapirolizumab-pegol-seen-to-reduce-sle-disease-activity-in-phase-3-trial 2024-11-22T04:15:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dapirolizumab-pegol-seen-to-reduce-sle-disease-activity-in-phase-3-trial 2024-11-22T04:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-tipranks-com 2024-11-22T04:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-tipranks-com 2024-11-22T04:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-cancer-drug-developed-by-b-c-s-zymeworks-delta-optimist 2024-11-22T04:04:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-cancer-drug-developed-by-b-c-s-zymeworks-delta-optimist 2024-11-22T04:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-jazz-pharmaceuticals-announce-fda-approval-of-ziihera-markets-insider 2024-11-22T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-jazz-pharmaceuticals-announce-fda-approval-of-ziihera-markets-insider 2024-11-22T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug-outsourcing-pharma-com 2024-11-22T03:10:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug-outsourcing-pharma-com 2024-11-22T03:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/new-stomach-cancer-drug-vyloy-faces-access-challenges-despite-approval-kbr 2024-11-22T02:55:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-stomach-cancer-drug-vyloy-faces-access-challenges-despite-approval-kbr 2024-11-22T02:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/ui-researchers-receive-funding-for-clinical-trials-in-new-cancer-treatment-the-daily-iowan 2024-11-22T02:27:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ui-researchers-receive-funding-for-clinical-trials-in-new-cancer-treatment-the-daily-iowan 2024-11-22T02:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/immunitybio-partners-with-ncartes-to-streamline-clinical-trial-data-collection-through-emr-automation 2024-11-22T01:19:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunitybio-partners-with-ncartes-to-streamline-clinical-trial-data-collection-through-emr-automation 2024-11-22T01:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-clinical-trial-of-abi-110-a-groundbreaking-gene-therapy-for-wet-amd-including-pcv 2024-11-22T01:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-clinical-trial-of-abi-110-a-groundbreaking-gene-therapy-for-wet-amd-including-pcv 2024-11-22T01:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-oncolytic-virus-orienx010-and-toripalimab-in-resectable-acral-melanoma-a-phase-ib-trial 2024-11-22T01:07:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-oncolytic-virus-orienx010-and-toripalimab-in-resectable-acral-melanoma-a-phase-ib-trial 2024-11-22T01:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/ipsell-is-a-biotechnology-company-that-specializes-in-using-induced-pluripotent-stem-cells-to-produc 2024-11-22T01:05:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsell-is-a-biotechnology-company-that-specializes-in-using-induced-pluripotent-stem-cells-to-produc 2024-11-22T01:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-neuroimaging-marker-may-identify-persons-at-risk-of-dementia-in-future-clinical-trials 2024-11-22T01:04:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-neuroimaging-marker-may-identify-persons-at-risk-of-dementia-in-future-clinical-trials 2024-11-22T01:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-secures-ema-orphan-designation-for-ocu410st-advancing-stargardt-disease-treatment 2024-11-22T01:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-secures-ema-orphan-designation-for-ocu410st-advancing-stargardt-disease-treatment 2024-11-22T01:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-the-national-law-review 2024-11-22T00:33:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-the-national-law-review 2024-11-22T00:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-plans-5-new-products-zeranovia-weight-management-drug-shows-promise 2024-11-22T00:25:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioadaptives-plans-5-new-products-zeranovia-weight-management-drug-shows-promise 2024-11-22T00:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/umdf-and-khondrion-announce-the-mito-fund-s-investment-in-globenewswire 2024-11-22T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/umdf-and-khondrion-announce-the-mito-fund-s-investment-in-globenewswire 2024-11-22T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/b-c-biotech-zymeworks-gets-fda-approval-for-new-cancer-drug-business-in-vancouver 2024-11-21T23:50:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/b-c-biotech-zymeworks-gets-fda-approval-for-new-cancer-drug-business-in-vancouver 2024-11-21T23:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-insightec-exablate-prime-for-use-on-philips-systems-massdevice 2024-11-21T23:40:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-insightec-exablate-prime-for-use-on-philips-systems-massdevice 2024-11-21T23:40:48+00:00 weekly 0.7 https://trial.medpath.com/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/ich-embraces-innovation-in-clinical-trial-design-citeline 2024-11-21T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ich-embraces-innovation-in-clinical-trial-design-citeline 2024-11-21T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-biliary-tract-cancer-treatment-from-jazz-bioworld 2024-11-21T22:57:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-biliary-tract-cancer-treatment-from-jazz-bioworld 2024-11-21T22:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-resubmits-new-drug-application-for-migraine-treatment-diabetes-drug-is-approved 2024-11-21T22:51:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-resubmits-new-drug-application-for-migraine-treatment-diabetes-drug-is-approved 2024-11-21T22:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/pompe-disease-pipeline-insight-2024-with-comprehensive-globenewswire 2024-11-21T22:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pompe-disease-pipeline-insight-2024-with-comprehensive-globenewswire 2024-11-21T22:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-keytruda-plus-berahyaluronidase-alfa-combo-meets-phase-3-trial-end 2024-11-21T22:25:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-keytruda-plus-berahyaluronidase-alfa-combo-meets-phase-3-trial-end 2024-11-21T22:25:51+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-avd-improves-progression-free-survival-in-advanced-stage-hodgkin-lymphoma 2024-11-21T22:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-avd-improves-progression-free-survival-in-advanced-stage-hodgkin-lymphoma 2024-11-21T22:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-gurufocus 2024-11-21T22:13:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-gurufocus 2024-11-21T22:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-launches-first-fda-approved-npc-treatment-investing-com 2024-11-21T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-launches-first-fda-approved-npc-treatment-investing-com 2024-11-21T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-biliary-tract-cancer-antibody-treatment-managed-healthcare-executive 2024-11-21T21:43:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approvals-biliary-tract-cancer-antibody-treatment-managed-healthcare-executive 2024-11-21T21:43:33+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-research-participant-finds-hope-in-helping-others-banner-health 2024-11-21T21:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-research-participant-finds-hope-in-helping-others-banner-health 2024-11-21T21:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-targeted-oncology 2024-11-21T21:38:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-targeted-oncology 2024-11-21T21:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-usa-today 2024-11-21T21:33:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-usa-today 2024-11-21T21:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T21:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T21:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-21T21:24:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-21T21:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trials-of-treatment-combo-for-hepatitis-d-expected-in-2025-liver-disease-news 2024-11-21T21:23:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trials-of-treatment-combo-for-hepatitis-d-expected-in-2025-liver-disease-news 2024-11-21T21:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-seeks-fda-approval-for-breakthrough-melanoma-treatment-rp1-stock-titan 2024-11-21T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-seeks-fda-approval-for-breakthrough-melanoma-treatment-rp1-stock-titan 2024-11-21T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-publication-from-the-undiagnosed-pediatric-patients-team-fakultni-nemocnice-brno 2024-11-21T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-publication-from-the-undiagnosed-pediatric-patients-team-fakultni-nemocnice-brno 2024-11-21T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-inc-announces-fda-accelerated-approval-of-ziihera-r-for-her2-positive 2024-11-21T21:18:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-inc-announces-fda-accelerated-approval-of-ziihera-r-for-her2-positive 2024-11-21T21:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-address-burnout-enroll-your-practice 2024-11-21T21:12:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-to-address-burnout-enroll-your-practice 2024-11-21T21:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/r-pharm-reported-phase-iii-trial-results-of-pembrolizumab-gxp-news 2024-11-21T20:44:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/r-pharm-reported-phase-iii-trial-results-of-pembrolizumab-gxp-news 2024-11-21T20:44:46+00:00 weekly 0.7 https://trial.medpath.com/news/rare-milestone-for-canadian-biotech-as-zymeworks-developed-drug-gets-fda-approval 2024-11-21T20:29:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rare-milestone-for-canadian-biotech-as-zymeworks-developed-drug-gets-fda-approval 2024-11-21T20:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-hrii-for-her2-biliary-tract-cancer 2024-11-21T20:22:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-hrii-for-her2-biliary-tract-cancer 2024-11-21T20:22:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-in-her2-biliary-tract-cancer-targeted-oncology 2024-11-21T20:13:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-in-her2-biliary-tract-cancer-targeted-oncology 2024-11-21T20:13:14+00:00 weekly 0.7 https://trial.medpath.com/news/rems-update-mavacamten-still-effective-in-treating-real-world-patients-with-hcm 2024-11-21T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rems-update-mavacamten-still-effective-in-treating-real-world-patients-with-hcm 2024-11-21T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-for-head-and-neck-cancer-british-dental-journal-nature 2024-11-21T19:59:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-for-head-and-neck-cancer-british-dental-journal-nature 2024-11-21T19:59:38+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-announces-initiation-of-phase-2-clinical-trial-of-rlyb212-biospace 2024-11-21T19:10:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-announces-initiation-of-phase-2-clinical-trial-of-rlyb212-biospace 2024-11-21T19:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-green-lit-for-first-brain-chip-trial-outside-us-newsweek 2024-11-21T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-green-lit-for-first-brain-chip-trial-outside-us-newsweek 2024-11-21T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-helps-survivor-through-three-cancer-diagnoses 2024-11-21T19:01:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-helps-survivor-through-three-cancer-diagnoses 2024-11-21T19:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-zanidatamab-hrii-for-previously-treated-unresectable 2024-11-21T18:59:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-zanidatamab-hrii-for-previously-treated-unresectable 2024-11-21T18:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-ab-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial 2024-11-21T18:58:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-ab-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial 2024-11-21T18:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/weed-for-ptsd-eager-for-better-cannabis-science-f-d-a-clears-study 2024-11-21T18:43:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weed-for-ptsd-eager-for-better-cannabis-science-f-d-a-clears-study 2024-11-21T18:43:16+00:00 weekly 0.7 https://trial.medpath.com/news/in-brief-polarean-imaging-gets-fda-approval-for-mri-chest-coil-morningstar 2024-11-21T18:39:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-brief-polarean-imaging-gets-fda-approval-for-mri-chest-coil-morningstar 2024-11-21T18:39:57+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-secures-fda-approval-for-ziihera-in-biliary-tract-cancer-yahoo-finance 2024-11-21T18:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-secures-fda-approval-for-ziihera-in-biliary-tract-cancer-yahoo-finance 2024-11-21T18:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-for-biliary-tract-cancer-medpage-today 2024-11-21T18:19:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-for-biliary-tract-cancer-medpage-today 2024-11-21T18:19:23+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-for-november-21-2024 2024-11-21T18:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-research-highlights-for-november-21-2024 2024-11-21T18:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-next-for-the-psychedelics-regulatory-and-clinical-landscape 2024-11-21T18:13:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-next-for-the-psychedelics-regulatory-and-clinical-landscape 2024-11-21T18:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-gets-330m-to-kick-off-global-leukemia-drug-pact-with-kyowa-kirin 2024-11-21T18:10:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-gets-330m-to-kick-off-global-leukemia-drug-pact-with-kyowa-kirin 2024-11-21T18:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bimzelx-for-hidradenitis-suppurativa-webmd 2024-11-21T17:40:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bimzelx-for-hidradenitis-suppurativa-webmd 2024-11-21T17:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/some-alzheimer-s-blood-tests-are-racing-toward-ivd-certification-alzforum 2024-11-21T17:36:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/some-alzheimer-s-blood-tests-are-racing-toward-ivd-certification-alzforum 2024-11-21T17:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/pbyi-begins-phase-ii-study-on-alisertib-combo-in-breast-cancer-barchart-com 2024-11-21T17:33:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbyi-begins-phase-ii-study-on-alisertib-combo-in-breast-cancer-barchart-com 2024-11-21T17:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/soft-launch-of-first-indigenous-antibiotic-to-combat-amr-nafithromycin-announced-by-dr 2024-11-21T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soft-launch-of-first-indigenous-antibiotic-to-combat-amr-nafithromycin-announced-by-dr 2024-11-21T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/laparoscopic-cytoreduction-after-neoadjuvant-chemotherapy-in-high-grade-jama-network 2024-11-21T17:22:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/laparoscopic-cytoreduction-after-neoadjuvant-chemotherapy-in-high-grade-jama-network 2024-11-21T17:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/sage-ends-dalzanemdor-development-following-phase-ii-trial-failure-yahoo-finance 2024-11-21T17:13:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-ends-dalzanemdor-development-following-phase-ii-trial-failure-yahoo-finance 2024-11-21T17:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-gets-first-ever-approval-outside-of-u-s-teslarati 2024-11-21T17:10:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-gets-first-ever-approval-outside-of-u-s-teslarati 2024-11-21T17:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable 2024-11-21T17:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable 2024-11-21T17:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-for-november-21-2024-newswise 2024-11-21T17:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-research-highlights-for-november-21-2024-newswise 2024-11-21T17:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable 2024-11-21T17:02:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable 2024-11-21T17:02:33+00:00 weekly 0.7 https://trial.medpath.com/news/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable-yahoo 2024-11-21T16:59:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novocure-secures-fda-approval-for-add-ons-to-brain-cancer-treatment-wearable-yahoo 2024-11-21T16:59:27+00:00 weekly 0.7 https://trial.medpath.com/news/offworld-life-science-brain-organoids-grown-in-microgravity-the-astrobiology-web 2024-11-21T16:58:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/offworld-life-science-brain-organoids-grown-in-microgravity-the-astrobiology-web 2024-11-21T16:58:54+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-drug-conjugate-targeting-cldn1-receives-fda-fast-track-designation 2024-11-21T16:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-drug-conjugate-targeting-cldn1-receives-fda-fast-track-designation 2024-11-21T16:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/ich-embraces-innovation-in-clinical-trial-design-pink-sheet-key-regulatory-and-policy-insights 2024-11-21T16:57:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ich-embraces-innovation-in-clinical-trial-design-pink-sheet-key-regulatory-and-policy-insights 2024-11-21T16:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/sage-ends-dalzanemdor-development-following-phase-ii-trial-failure-clinical-trials-arena 2024-11-21T16:55:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-ends-dalzanemdor-development-following-phase-ii-trial-failure-clinical-trials-arena 2024-11-21T16:55:03+00:00 weekly 0.7 https://trial.medpath.com/news/intravenous-injections-of-zanidatamab-hrii-receives-fda-accelerated-approval-for-ihc-btc 2024-11-21T16:48:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intravenous-injections-of-zanidatamab-hrii-receives-fda-accelerated-approval-for-ihc-btc 2024-11-21T16:48:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-for-biliary-tract-cancers-with-high-her2-levels 2024-11-21T16:44:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-for-biliary-tract-cancers-with-high-her2-levels 2024-11-21T16:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-plus-adt-in-metastatic-hormone-sensitive-prostate-cancer 2024-11-21T16:23:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-plus-adt-in-metastatic-hormone-sensitive-prostate-cancer 2024-11-21T16:23:35+00:00 weekly 0.7 https://trial.medpath.com/news/expanded-cancer-care-options-translate-to-hope-for-both-urban-rural-patients-siouxfalls-business 2024-11-21T16:19:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expanded-cancer-care-options-translate-to-hope-for-both-urban-rural-patients-siouxfalls-business 2024-11-21T16:19:41+00:00 weekly 0.7 https://trial.medpath.com/news/olverembatinib-after-failure-of-tyrosine-kinase-inhibitors-including-ponatinib-or-asciminib 2024-11-21T16:16:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olverembatinib-after-failure-of-tyrosine-kinase-inhibitors-including-ponatinib-or-asciminib 2024-11-21T16:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/from-bench-to-bedside-osteoarthritis-gene-therapy-developed-in-the-lab-at-baylor-is-in 2024-11-21T16:15:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/from-bench-to-bedside-osteoarthritis-gene-therapy-developed-in-the-lab-at-baylor-is-in 2024-11-21T16:15:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T16:14:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T16:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/supira-medical-initiates-u-s-early-feasibility-study-efs-for-high-risk-pci 2024-11-21T16:14:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supira-medical-initiates-u-s-early-feasibility-study-efs-for-high-risk-pci 2024-11-21T16:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/kedrion-s-facility-in-bolognana-approved-by-fda-to-produce-ryplazim-contract-pharma 2024-11-21T16:10:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kedrion-s-facility-in-bolognana-approved-by-fda-to-produce-ryplazim-contract-pharma 2024-11-21T16:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-preoperative-prophylactic-application-of-betamethasone-on-postoperative-nausea 2024-11-21T16:08:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-preoperative-prophylactic-application-of-betamethasone-on-postoperative-nausea 2024-11-21T16:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/ai-improves-prediction-of-response-to-pd-l1-inhibitors-in-urothelial-carcinoma 2024-11-21T16:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-improves-prediction-of-response-to-pd-l1-inhibitors-in-urothelial-carcinoma 2024-11-21T16:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-expands-indications-for-nubeqa-with-new-drug-application-clinical-trials-arena 2024-11-21T16:05:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-expands-indications-for-nubeqa-with-new-drug-application-clinical-trials-arena 2024-11-21T16:05:37+00:00 weekly 0.7 https://trial.medpath.com/news/invikafusp-alfa-shows-potential-in-pd-1-refractory-solid-tumors-targeted-oncology 2024-11-21T16:03:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invikafusp-alfa-shows-potential-in-pd-1-refractory-solid-tumors-targeted-oncology 2024-11-21T16:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-s-promising-therapeutic-advancements-justify-buy-rating 2024-11-21T16:02:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-s-promising-therapeutic-advancements-justify-buy-rating 2024-11-21T16:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-the-detroit-news 2024-11-21T15:24:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-the-detroit-news 2024-11-21T15:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/jama-commentary-highlights-need-for-virtual-vigilance-in-decentralized-clinical-trials 2024-11-21T15:24:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jama-commentary-highlights-need-for-virtual-vigilance-in-decentralized-clinical-trials 2024-11-21T15:24:38+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-secures-approval-for-hemophilia-drug-hympavzi-in-the-eu-yahoo-finance 2024-11-21T15:24:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-secures-approval-for-hemophilia-drug-hympavzi-in-the-eu-yahoo-finance 2024-11-21T15:24:36+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-secures-approval-for-hemophilia-drug-hympavzi-in-the-eu-msn 2024-11-21T15:17:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-secures-approval-for-hemophilia-drug-hympavzi-in-the-eu-msn 2024-11-21T15:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/gout-pipeline-research-report-2024-comprehensive-insights 2024-11-21T15:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gout-pipeline-research-report-2024-comprehensive-insights 2024-11-21T15:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-gets-green-light-for-more-clinical-trials 2024-11-21T15:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-gets-green-light-for-more-clinical-trials 2024-11-21T15:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-jazz-pharmaceuticals-ziihera-for-her2-positive-biliary 2024-11-21T15:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-jazz-pharmaceuticals-ziihera-for-her2-positive-biliary 2024-11-21T15:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/ai-drug-discovery-startup-enveda-raises-130-million-bnn-bloomberg 2024-11-21T15:06:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-drug-discovery-startup-enveda-raises-130-million-bnn-bloomberg 2024-11-21T15:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-gets-green-light-to-launch-bci-trial-in-canada-massdevice 2024-11-21T15:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuralink-gets-green-light-to-launch-bci-trial-in-canada-massdevice 2024-11-21T15:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-therapeutics-to-participate-in-the-2024-international-symposium-on-als-mnd 2024-11-21T15:03:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-therapeutics-to-participate-in-the-2024-international-symposium-on-als-mnd 2024-11-21T15:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-urology-times 2024-11-21T14:55:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-urology-times 2024-11-21T14:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-21T14:51:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-21T14:51:56+00:00 weekly 0.7 https://trial.medpath.com/news/emstoptm-announces-completion-of-capture-1-early-feasibility-clinical-trial 2024-11-21T14:44:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emstoptm-announces-completion-of-capture-1-early-feasibility-clinical-trial 2024-11-21T14:44:25+00:00 weekly 0.7 https://trial.medpath.com/news/dosing-begins-in-phase-3-trial-of-parkinson-s-therapy-solengepras 2024-11-21T14:33:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dosing-begins-in-phase-3-trial-of-parkinson-s-therapy-solengepras 2024-11-21T14:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-gets-approval-to-start-human-trials-in-canada-yahoo-news 2024-11-21T14:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuralink-gets-approval-to-start-human-trials-in-canada-yahoo-news 2024-11-21T14:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/new-amsterdam-sees-success-in-phase-iii-cardiovascular-disease-trial 2024-11-21T14:31:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-amsterdam-sees-success-in-phase-iii-cardiovascular-disease-trial 2024-11-21T14:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/anxiety-drug-trials-keep-stifel-optimistic-on-vistagen-stock-s-upside-potential-investing-com 2024-11-21T14:30:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anxiety-drug-trials-keep-stifel-optimistic-on-vistagen-stock-s-upside-potential-investing-com 2024-11-21T14:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T14:27:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T14:27:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ziihera-for-some-with-biliary-tract-cancer-cure-today 2024-11-21T14:22:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ziihera-for-some-with-biliary-tract-cancer-cure-today 2024-11-21T14:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial-biospace 2024-11-21T14:17:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial-biospace 2024-11-21T14:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T14:13:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-kedrion-s-bolognana-facility-for-production-of-first-and-only-treatment-for 2024-11-21T14:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-launches-european-advisory-board-for-phase-3-hybryte-ctcl-trial 2024-11-21T14:13:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soligenix-launches-european-advisory-board-for-phase-3-hybryte-ctcl-trial 2024-11-21T14:13:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zihera-for-advanced-her2-positive-biliary-tract-cancer-healio 2024-11-21T14:12:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zihera-for-advanced-her2-positive-biliary-tract-cancer-healio 2024-11-21T14:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/huntington-s-disease-a-therapeutic-field-on-a-bumpy-ride-labiotech 2024-11-21T14:09:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/huntington-s-disease-a-therapeutic-field-on-a-bumpy-ride-labiotech 2024-11-21T14:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/tune-therapeutics-to-initiate-clinical-trial-of-first-in-class-epigenetic-silencer-in-chronic-hepatitis-b 2024-11-21T14:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tune-therapeutics-to-initiate-clinical-trial-of-first-in-class-epigenetic-silencer-in-chronic-hepatitis-b 2024-11-21T14:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/zerlasiran-achieves-durable-lp-a-reductions-at-60-weeks-with-stephen-j-nicholls-md-phd 2024-11-21T14:06:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zerlasiran-achieves-durable-lp-a-reductions-at-60-weeks-with-stephen-j-nicholls-md-phd 2024-11-21T14:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/kura-kyowa-kirin-join-forces-to-develop-commercialize-ziftomenib-contract-pharma 2024-11-21T14:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-kyowa-kirin-join-forces-to-develop-commercialize-ziftomenib-contract-pharma 2024-11-21T14:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-for-pretreated-her2-positive-biliary-tract-cancer 2024-11-21T13:56:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-for-pretreated-her2-positive-biliary-tract-cancer 2024-11-21T13:56:33+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-dosing-of-first-patient-in-gentle-phase-i-iia-clinical-trial-of-amt-260 2024-11-21T13:54:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-dosing-of-first-patient-in-gentle-phase-i-iia-clinical-trial-of-amt-260 2024-11-21T13:54:15+00:00 weekly 0.7 https://trial.medpath.com/news/science-37-delivers-47-us-enrollment-in-gsk-s-phase-3-rare-disease-trial-stock-titan 2024-11-21T13:50:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/science-37-delivers-47-us-enrollment-in-gsk-s-phase-3-rare-disease-trial-stock-titan 2024-11-21T13:50:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T13:40:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T13:40:14+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-starts-pivotal-clinical-trial-testing-dmd-gene-therapy-rgx-202 2024-11-21T13:37:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-starts-pivotal-clinical-trial-testing-dmd-gene-therapy-rgx-202 2024-11-21T13:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-morningstar 2024-11-21T13:36:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-morningstar 2024-11-21T13:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-cision-news 2024-11-21T13:36:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-cision-news 2024-11-21T13:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/life-science-tools-market-projected-to-reach-455-billion-by-2033-growing-at-10-9-cagr 2024-11-21T13:25:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/life-science-tools-market-projected-to-reach-455-billion-by-2033-growing-at-10-9-cagr 2024-11-21T13:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/rwjbarnabas-health-expands-access-to-clinical-trials-through-academic-community-partnership 2024-11-21T13:24:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rwjbarnabas-health-expands-access-to-clinical-trials-through-academic-community-partnership 2024-11-21T13:24:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-biospace 2024-11-21T13:19:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-biospace 2024-11-21T13:19:38+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-pr-newswire 2024-11-21T13:19:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-pr-newswire 2024-11-21T13:19:02+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-yahoo-finance 2024-11-21T13:18:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-yahoo-finance 2024-11-21T13:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-secures-3-million-in-stock-offering-investing-com 2024-11-21T13:18:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intensity-therapeutics-secures-3-million-in-stock-offering-investing-com 2024-11-21T13:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-reaches-recruitment-target-in-phase-3-study-diagnode-3-marketscreener 2024-11-21T13:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-reaches-recruitment-target-in-phase-3-study-diagnode-3-marketscreener 2024-11-21T13:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-pr-newswire 2024-11-21T13:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-pr-newswire 2024-11-21T13:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/insightec-secures-fda-approval-and-ce-marking-for-exablate-r-prime-on 2024-11-21T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insightec-secures-fda-approval-and-ce-marking-for-exablate-r-prime-on 2024-11-21T13:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/newamsterdam-pharma-reports-promising-phase-3-trial-results-yahoo-finance 2024-11-21T12:43:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newamsterdam-pharma-reports-promising-phase-3-trial-results-yahoo-finance 2024-11-21T12:43:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-r-for 2024-11-21T12:38:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-r-for 2024-11-21T12:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/thrombocytopenia-treatment-market-2034-clinical-trials-openpr-com 2024-11-21T12:32:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thrombocytopenia-treatment-market-2034-clinical-trials-openpr-com 2024-11-21T12:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/perspective-therapeutics-to-pursue-dose-escalation-of-212pb-vmt-a-net-in-its-quantisnow 2024-11-21T12:31:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perspective-therapeutics-to-pursue-dose-escalation-of-212pb-vmt-a-net-in-its-quantisnow 2024-11-21T12:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-cleared-for-brain-chip-trials-in-canada-financial-post 2024-11-21T12:31:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-cleared-for-brain-chip-trials-in-canada-financial-post 2024-11-21T12:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-dosing-of-first-patient-in-gentle-phase-i-iia-clinical-trial-of-amt-260 2024-11-21T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-dosing-of-first-patient-in-gentle-phase-i-iia-clinical-trial-of-amt-260 2024-11-21T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/marvel-biosciences-secures-300k-grant-for-breakthrough-alzheimer-s-drug-development 2024-11-21T12:25:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marvel-biosciences-secures-300k-grant-for-breakthrough-alzheimer-s-drug-development 2024-11-21T12:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-stock-titan 2024-11-21T12:19:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novocure-s-innovative-hfe-transducer-arrays-for-use-with-optune-gio-stock-titan 2024-11-21T12:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-represents-almost-half-of-merck-s-sales-and-a-new-formulation-could-fend-off-rivals 2024-11-21T12:17:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keytruda-represents-almost-half-of-merck-s-sales-and-a-new-formulation-could-fend-off-rivals 2024-11-21T12:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/interim-report-q3-2024-curasight-cision-news 2024-11-21T12:15:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interim-report-q3-2024-curasight-cision-news 2024-11-21T12:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/eu-clinical-trials-regulation-no-536-2014-enhances-harmonization-and-transparency 2024-11-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-clinical-trials-regulation-no-536-2014-enhances-harmonization-and-transparency 2024-11-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-data-at-the-ash-2024-annual-meeting-highlights-promising-hematology-pipeline 2024-11-21T11:51:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-data-at-the-ash-2024-annual-meeting-highlights-promising-hematology-pipeline 2024-11-21T11:51:48+00:00 weekly 0.7 https://trial.medpath.com/news/ai-method-can-measure-cancer-severity-using-pathology-reports-to-shorten-selection-process 2024-11-21T11:42:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-method-can-measure-cancer-severity-using-pathology-reports-to-shorten-selection-process 2024-11-21T11:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-et-healthworld 2024-11-21T11:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-et-healthworld 2024-11-21T11:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/melt-reports-topline-outcomes-from-trial-of-melt-300-for-cataract-surgery 2024-11-21T11:25:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melt-reports-topline-outcomes-from-trial-of-melt-300-for-cataract-surgery 2024-11-21T11:25:19+00:00 weekly 0.7 https://trial.medpath.com/news/new-alliance-for-the-development-of-a-sublingual-oxytocin-formulation-to-prevent-biospace 2024-11-21T11:22:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alliance-for-the-development-of-a-sublingual-oxytocin-formulation-to-prevent-biospace 2024-11-21T11:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/lipella-pharmaceuticals-announces-completion-of-first-cohort-in-phase-2a-trial-of-lp-310 2024-11-21T11:22:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipella-pharmaceuticals-announces-completion-of-first-cohort-in-phase-2a-trial-of-lp-310 2024-11-21T11:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T11:22:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T11:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-financial-post 2024-11-21T11:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-financial-post 2024-11-21T11:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T11:15:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T11:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-inc-globenewswire-via-ritzau 2024-11-21T11:14:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-inc-globenewswire-via-ritzau 2024-11-21T11:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drug-zepbound-may-lower-heart-failure-deaths 2024-11-21T11:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-drug-zepbound-may-lower-heart-failure-deaths 2024-11-21T11:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hs-treatment-bimzelx-pharmaceutical-executive 2024-11-21T11:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-hs-treatment-bimzelx-pharmaceutical-executive 2024-11-21T11:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/skin-patch-could-monitor-your-blood-pressure 2024-11-21T11:04:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skin-patch-could-monitor-your-blood-pressure 2024-11-21T11:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-and-acute-lymphoblastic-leukemia 2024-11-21T11:04:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-and-acute-lymphoblastic-leukemia 2024-11-21T11:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/there-may-be-a-better-way-to-treat-hematoma-brain-bleeds 2024-11-21T11:03:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/there-may-be-a-better-way-to-treat-hematoma-brain-bleeds 2024-11-21T11:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-globenewswire 2024-11-21T11:02:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-globenewswire 2024-11-21T11:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-and-acute-lymphoblastic-leukemia 2024-11-21T10:24:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-and-acute-lymphoblastic-leukemia 2024-11-21T10:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-globenewswire 2024-11-21T10:17:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-globenewswire 2024-11-21T10:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/puma-commences-phase-ii-trial-of-alisertib-for-breast-cancer-treatment-clinical-trials-arena 2024-11-21T10:04:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-commences-phase-ii-trial-of-alisertib-for-breast-cancer-treatment-clinical-trials-arena 2024-11-21T10:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-help-grandfather-with-incurable-prostate-cancer-turn-back-the-clock-fox-47 2024-11-21T09:39:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-help-grandfather-with-incurable-prostate-cancer-turn-back-the-clock-fox-47 2024-11-21T09:39:13+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-trials-for-epilepsy-proliferate-but-clin-neurology-today 2024-11-21T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-medicine-trials-for-epilepsy-proliferate-but-clin-neurology-today 2024-11-21T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-globenewswire 2024-11-21T09:11:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-globenewswire 2024-11-21T09:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-clinical-trial-evaluating-hydralazine-s-efficacy-in-early-stage-alzheimer-s-disease 2024-11-21T09:06:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-clinical-trial-evaluating-hydralazine-s-efficacy-in-early-stage-alzheimer-s-disease 2024-11-21T09:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug 2024-11-21T08:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug 2024-11-21T08:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-fda-approval-for-generic-version-of-adderall-xr-express-pharma 2024-11-21T08:35:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-receives-fda-approval-for-generic-version-of-adderall-xr-express-pharma 2024-11-21T08:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/mural-oncology-announces-publication-highlighting-promising-clinical-antitumor-activity 2024-11-21T08:17:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mural-oncology-announces-publication-highlighting-promising-clinical-antitumor-activity 2024-11-21T08:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034-biospace 2024-11-21T08:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034-biospace 2024-11-21T08:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034-biospace 2024-11-21T08:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034-biospace 2024-11-21T08:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/china-dominates-apac-s-emergence-as-global-trials-hub-citeline 2024-11-21T08:15:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-dominates-apac-s-emergence-as-global-trials-hub-citeline 2024-11-21T08:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharm-advances-launch-of-obesity-drug-efpeglenatide-to-late-2026-kbr 2024-11-21T07:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharm-advances-launch-of-obesity-drug-efpeglenatide-to-late-2026-kbr 2024-11-21T07:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharma-to-move-up-launch-of-anti-obesity-drug-ked-global 2024-11-21T07:51:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharma-to-move-up-launch-of-anti-obesity-drug-ked-global 2024-11-21T07:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/inxmed-fak-inhibitor-ifebemtinib-received-breakthrough-therapy-designation-by-morningstar 2024-11-21T07:44:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inxmed-fak-inhibitor-ifebemtinib-received-breakthrough-therapy-designation-by-morningstar 2024-11-21T07:44:42+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-bnn-bloomberg 2024-11-21T06:54:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-bnn-bloomberg 2024-11-21T06:54:11+00:00 weekly 0.7 https://trial.medpath.com/news/biomind-labs-welcomes-u-s-policy-shift-as-a-historic-milestone-for-psychedelic-therapies 2024-11-21T06:44:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomind-labs-welcomes-u-s-policy-shift-as-a-historic-milestone-for-psychedelic-therapies 2024-11-21T06:44:57+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsy-summit-2025-to-showcase-latest-advances-in-cancer-detection-and-monitoring 2024-11-21T06:09:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liquid-biopsy-summit-2025-to-showcase-latest-advances-in-cancer-detection-and-monitoring 2024-11-21T06:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-gets-green-light-to-launch-brain-chip-trial-in-canada-benzinga 2024-11-21T05:45:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-gets-green-light-to-launch-brain-chip-trial-in-canada-benzinga 2024-11-21T05:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-hold-rating-amidst-promising-hdv-study-results-and-future-hbv-developments 2024-11-21T05:28:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-hold-rating-amidst-promising-hdv-study-results-and-future-hbv-developments 2024-11-21T05:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-deccan-herald 2024-11-21T05:26:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-deccan-herald 2024-11-21T05:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-accelerates-launch-of-obesity-drug-to-2nd-half-of-2026 2024-11-21T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-accelerates-launch-of-obesity-drug-to-2nd-half-of-2026 2024-11-21T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/marianna-fontana-md-phd-nex-z-shows-promise-in-attr-cm-phase-1-trial-hcplive 2024-11-21T05:05:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marianna-fontana-md-phd-nex-z-shows-promise-in-attr-cm-phase-1-trial-hcplive 2024-11-21T05:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-help-grandfather-with-incurable-prostate-cancer-turn-back-the-clock-fox-47 2024-11-21T04:47:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-help-grandfather-with-incurable-prostate-cancer-turn-back-the-clock-fox-47 2024-11-21T04:47:07+00:00 weekly 0.7 https://trial.medpath.com/news/india-launches-first-indigenous-antibiotic-nafithromycin-to-combat-drug-resistance 2024-11-21T04:36:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-launches-first-indigenous-antibiotic-nafithromycin-to-combat-drug-resistance 2024-11-21T04:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-drug-for-rare-disease-related-itch-meets-goal-in-phase-iii-study-yahoo-finance 2024-11-21T04:18:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-drug-for-rare-disease-related-itch-meets-goal-in-phase-iii-study-yahoo-finance 2024-11-21T04:18:58+00:00 weekly 0.7 https://trial.medpath.com/news/georg-schett-md-on-exploring-car-t-for-autoimmune-disease-cgtlive-r 2024-11-21T04:10:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/georg-schett-md-on-exploring-car-t-for-autoimmune-disease-cgtlive-r 2024-11-21T04:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/university-hospitals-only-health-system-in-northeast-ohio-offering-fda-approved-newswise 2024-11-21T04:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-hospitals-only-health-system-in-northeast-ohio-offering-fda-approved-newswise 2024-11-21T04:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/city-of-hope-revolutionizes-cancer-care-through-patient-centered-approach-and-expanded-access 2024-11-21T04:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/city-of-hope-revolutionizes-cancer-care-through-patient-centered-approach-and-expanded-access 2024-11-21T04:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-announces-fda-approval-of-ziihera-in-btc-markets-insider 2024-11-21T04:00:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-announces-fda-approval-of-ziihera-in-btc-markets-insider 2024-11-21T04:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/greater-bay-area-international-clinical-trial-institute-officially-opened-in-hong-kong-park-of 2024-11-21T03:20:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/greater-bay-area-international-clinical-trial-institute-officially-opened-in-hong-kong-park-of 2024-11-21T03:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-announces-european-medicines-agency-grants-orphan-medicinal-the-globe-and-mail 2024-11-21T03:16:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-announces-european-medicines-agency-grants-orphan-medicinal-the-globe-and-mail 2024-11-21T03:16:45+00:00 weekly 0.7 https://trial.medpath.com/news/digital-experience-platforms-revolutionize-pharmaceutical-claims-management-and-hcp-engagement 2024-11-21T02:19:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-experience-platforms-revolutionize-pharmaceutical-claims-management-and-hcp-engagement 2024-11-21T02:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/dr-pobel-on-the-prognostic-value-of-phenotypic-and-genomic-characterization-in-de-novo-mcspc 2024-11-21T02:03:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-pobel-on-the-prognostic-value-of-phenotypic-and-genomic-characterization-in-de-novo-mcspc 2024-11-21T02:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/biktarvy-shows-long-term-efficacy-and-safety-in-hiv-hbv-coinfection-after-three-years 2024-11-21T01:50:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biktarvy-shows-long-term-efficacy-and-safety-in-hiv-hbv-coinfection-after-three-years 2024-11-21T01:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-zanidatamab-injection-for-metastatic-her2-biliary-tract-cancer 2024-11-21T01:47:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oks-zanidatamab-injection-for-metastatic-her2-biliary-tract-cancer 2024-11-21T01:47:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-for-previously-treated-unresectable-or-metastatic-her2-onclive 2024-11-21T01:35:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-for-previously-treated-unresectable-or-metastatic-her2-onclive 2024-11-21T01:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/biomind-labs-hails-u-s-support-for-psychedelic-therapies-tipranks-com 2024-11-21T00:57:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomind-labs-hails-u-s-support-for-psychedelic-therapies-tipranks-com 2024-11-21T00:57:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-long-awaited-clinical-trial-of-smoked-marijuana-to-treat-ptsd-in-veterans 2024-11-21T00:45:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-long-awaited-clinical-trial-of-smoked-marijuana-to-treat-ptsd-in-veterans 2024-11-21T00:45:52+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharma-s-ziihera-wins-fda-approval-with-52-response-rate-in-cancer-trial 2024-11-21T00:26:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharma-s-ziihera-wins-fda-approval-with-52-response-rate-in-cancer-trial 2024-11-21T00:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-committees-vote-to-dismiss-clozapine-rems-psychiatric-times 2024-11-21T00:12:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-committees-vote-to-dismiss-clozapine-rems-psychiatric-times 2024-11-21T00:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-s-promising-advancements-in-hepatitis-treatments-justify-buy-rating 2024-11-21T00:04:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-s-promising-advancements-in-hepatitis-treatments-justify-buy-rating 2024-11-21T00:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/hrx-215-drug-targets-indications-patents 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hrx-215-drug-targets-indications-patents 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/conduit-pharmaceuticals-secures-japanese-patent-for-azd1656-glucokinase-activator-targeting-autoimmune-disorders 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conduit-pharmaceuticals-secures-japanese-patent-for-azd1656-glucokinase-activator-targeting-autoimmune-disorders 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pila-pharma-announces-initiation-of-study-in 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pila-pharma-announces-initiation-of-study-in 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lisaftoclax-nda-accepted-for-review-in-china-for-relapsed-refractory-cll-sll-onclive 2024-11-20T23:58:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lisaftoclax-nda-accepted-for-review-in-china-for-relapsed-refractory-cll-sll-onclive 2024-11-20T23:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-3-data-of-jnj-2113-for-plaque-psoriasis-in-patients-aged-12-years-older 2024-11-20T23:56:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-phase-3-data-of-jnj-2113-for-plaque-psoriasis-in-patients-aged-12-years-older 2024-11-20T23:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/biomind-labs-bmnd08-achieves-100-efficacy-in-phase-ii-depression-trial-bmndf-stock-news 2024-11-20T23:47:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomind-labs-bmnd08-achieves-100-efficacy-in-phase-ii-depression-trial-bmndf-stock-news 2024-11-20T23:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/newamsterdam-s-obicetrapib-combo-nails-phase-iii-ldl-c-endpoints-bioworld 2024-11-20T23:46:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newamsterdam-s-obicetrapib-combo-nails-phase-iii-ldl-c-endpoints-bioworld 2024-11-20T23:46:15+00:00 weekly 0.7 https://trial.medpath.com/news/sage-shuts-down-huntington-s-program-after-phase-ii-failure-bioworld 2024-11-20T23:46:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-shuts-down-huntington-s-program-after-phase-ii-failure-bioworld 2024-11-20T23:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/osimertinib-approaches-eu-approval-in-locally-advanced-egfr-nsclc-after-chemoradiation 2024-11-20T23:45:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osimertinib-approaches-eu-approval-in-locally-advanced-egfr-nsclc-after-chemoradiation 2024-11-20T23:45:38+00:00 weekly 0.7 https://trial.medpath.com/news/corvent-wins-fda-clearance-for-respond-critical-care-ventilator-massdevice 2024-11-20T22:43:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvent-wins-fda-clearance-for-respond-critical-care-ventilator-massdevice 2024-11-20T22:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/sage-s-pipeline-prospects-narrow-further-as-dalzanemdor-fails-in-huntington-s-citeline 2024-11-20T22:42:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-s-pipeline-prospects-narrow-further-as-dalzanemdor-fails-in-huntington-s-citeline 2024-11-20T22:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-clinical-trials-for-medical-cannabis-to-treat-ptsd-in-military-veterans 2024-11-20T22:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-clinical-trials-for-medical-cannabis-to-treat-ptsd-in-military-veterans 2024-11-20T22:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-combination-for-subdural-hematoma-reduces-risk-of-recurrence 2024-11-20T22:35:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-combination-for-subdural-hematoma-reduces-risk-of-recurrence 2024-11-20T22:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-cardiolrx-gains-buy-rating-on-positive-phase-2-results-and-strong 2024-11-20T22:28:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-cardiolrx-gains-buy-rating-on-positive-phase-2-results-and-strong 2024-11-20T22:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ai-screening-tool-for-cardiac-amyloidosis-cardiovascular-business 2024-11-20T22:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-ai-screening-tool-for-cardiac-amyloidosis-cardiovascular-business 2024-11-20T22:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/target-switch-and-high-risk-cohorts-support-talquetamab-use-in-rrmm 2024-11-20T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/target-switch-and-high-risk-cohorts-support-talquetamab-use-in-rrmm 2024-11-20T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/the-fda-approves-labeling-update-for-sandoz-in-the-treatment-of-b-cell-cll-cure-today 2024-11-20T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-fda-approves-labeling-update-for-sandoz-in-the-treatment-of-b-cell-cll-cure-today 2024-11-20T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-poised-for-outperformance-keeps-buy-rating-on-pipeline-potential 2024-11-20T21:55:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-poised-for-outperformance-keeps-buy-rating-on-pipeline-potential 2024-11-20T21:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-phase-2-trial-of-cannabis-in-ptsd-managed-healthcare-executive 2024-11-20T21:28:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-phase-2-trial-of-cannabis-in-ptsd-managed-healthcare-executive 2024-11-20T21:28:38+00:00 weekly 0.7 https://trial.medpath.com/news/a-watershed-moment-glp-1-drug-succeeds-in-late-stage-mash-trial-medpage-today 2024-11-20T21:24:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-watershed-moment-glp-1-drug-succeeds-in-late-stage-mash-trial-medpage-today 2024-11-20T21:24:19+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-aflibercept-biosimilar-opuviz-previously-sb15-from 2024-11-20T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-aflibercept-biosimilar-opuviz-previously-sb15-from 2024-11-20T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-receives-prime-designation-from-the-european-medicines-agency-for 2024-11-20T21:20:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-receives-prime-designation-from-the-european-medicines-agency-for 2024-11-20T21:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/organovo-presents-clinical-data-of-fxr314-in-phase-2-mash-in-an-oral-yahoo-finance 2024-11-20T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/organovo-presents-clinical-data-of-fxr314-in-phase-2-mash-in-an-oral-yahoo-finance 2024-11-20T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-s-cancer-drug-nx-5948-secures-ema-prime-status-for-advanced-leukemia-treatment 2024-11-20T21:06:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-s-cancer-drug-nx-5948-secures-ema-prime-status-for-advanced-leukemia-treatment 2024-11-20T21:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/around-the-helix-cell-and-gene-therapy-company-updates-november-20-2024 2024-11-20T21:05:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/around-the-helix-cell-and-gene-therapy-company-updates-november-20-2024 2024-11-20T21:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-receives-prime-designation-from-the-european-medicines-agency-for 2024-11-20T21:03:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-receives-prime-designation-from-the-european-medicines-agency-for 2024-11-20T21:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bimzelx-for-adults-with-moderate-to-severe-hidradenitis-suppurativa-healio 2024-11-20T20:53:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bimzelx-for-adults-with-moderate-to-severe-hidradenitis-suppurativa-healio 2024-11-20T20:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fast-tracks-ale-p02-for-cldn1-poisitive-solid-cancers-oncology-nursing-news 2024-11-20T20:08:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-fast-tracks-ale-p02-for-cldn1-poisitive-solid-cancers-oncology-nursing-news 2024-11-20T20:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T20:04:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T20:04:48+00:00 weekly 0.7 https://trial.medpath.com/news/first-mpox-vaccine-for-children-approved-by-who-to-fight-virus-outbreak-euronews 2024-11-20T19:57:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-mpox-vaccine-for-children-approved-by-who-to-fight-virus-outbreak-euronews 2024-11-20T19:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-initiates-phase-iii-trial-for-heart-disease-drug-the-streetwise-reports 2024-11-20T19:56:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-initiates-phase-iii-trial-for-heart-disease-drug-the-streetwise-reports 2024-11-20T19:56:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bimzelx-for-inflammatory-skin-disease-managed-healthcare-executive 2024-11-20T19:30:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bimzelx-for-inflammatory-skin-disease-managed-healthcare-executive 2024-11-20T19:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approval-recommended-for-repotrectinib-in-ros1-nsclc-ntrk-solid-tumors 2024-11-20T19:03:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approval-recommended-for-repotrectinib-in-ros1-nsclc-ntrk-solid-tumors 2024-11-20T19:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ucb-s-psoriasis-drug-for-expanded-use-in-painful-inflammatory-skin-disease 2024-11-20T19:02:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ucb-s-psoriasis-drug-for-expanded-use-in-painful-inflammatory-skin-disease 2024-11-20T19:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/sylvester-duo-advances-research-on-aggressive-rare-gynecologic-cancers-inventum 2024-11-20T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sylvester-duo-advances-research-on-aggressive-rare-gynecologic-cancers-inventum 2024-11-20T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-molecule-heals-gut-blocks-tumors-mirage-news 2024-11-20T18:43:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-molecule-heals-gut-blocks-tumors-mirage-news 2024-11-20T18:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-iii-results-for-linerixibat-in-cholestatic-pruritus-treatment-for-pbc-patients 2024-11-20T18:42:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-iii-results-for-linerixibat-in-cholestatic-pruritus-treatment-for-pbc-patients 2024-11-20T18:42:47+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-iii-results-for-linerixibat-in-cholestatic-pruritus-treatment-for-pbc-patients 2024-11-20T18:36:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-iii-results-for-linerixibat-in-cholestatic-pruritus-treatment-for-pbc-patients 2024-11-20T18:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/brain-breakthrough-4-common-heart-drugs-may-also-lower-dementia-risk-study-finds 2024-11-20T18:18:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-breakthrough-4-common-heart-drugs-may-also-lower-dementia-risk-study-finds 2024-11-20T18:18:02+00:00 weekly 0.7 https://trial.medpath.com/news/the-dust-has-settled-sage-s-dalzanemdor-won-t-advance-for-cognitive-impairment-hdbuzz 2024-11-20T18:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-dust-has-settled-sage-s-dalzanemdor-won-t-advance-for-cognitive-impairment-hdbuzz 2024-11-20T18:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-wins-fda-nod-for-new-inpen-app-to-support-launch-with-simplera-cgm 2024-11-20T17:43:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-wins-fda-nod-for-new-inpen-app-to-support-launch-with-simplera-cgm 2024-11-20T17:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-omron-ai-powered-afib-detection-in-blood-pressure-monitors 2024-11-20T17:31:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-omron-ai-powered-afib-detection-in-blood-pressure-monitors 2024-11-20T17:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-alisca-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T17:30:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-alisca-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T17:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trials-of-c3g-therapies-docwire-news 2024-11-20T17:27:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trials-of-c3g-therapies-docwire-news 2024-11-20T17:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for 2024-11-20T17:24:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for 2024-11-20T17:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/zerlasiran-achieves-significant-sustained-reduction-in-lipoprotein-a-levels-with-infrequent-dosing 2024-11-20T17:15:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zerlasiran-achieves-significant-sustained-reduction-in-lipoprotein-a-levels-with-infrequent-dosing 2024-11-20T17:15:50+00:00 weekly 0.7 https://trial.medpath.com/news/the-influence-of-pd-1-inhibitor-label-restrictions-on-future-studies 2024-11-20T17:15:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-influence-of-pd-1-inhibitor-label-restrictions-on-future-studies 2024-11-20T17:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/neurovoices-charbel-moussa-phd-mbbs-on-therapeutic-potential-of-nilotinib-in 2024-11-20T17:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurovoices-charbel-moussa-phd-mbbs-on-therapeutic-potential-of-nilotinib-in 2024-11-20T17:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/sage-s-string-of-research-failures-continues-biopharma-dive 2024-11-20T17:01:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-s-string-of-research-failures-continues-biopharma-dive 2024-11-20T17:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/levi-04-improved-outcomes-in-knee-osteoarthritis-compared-with-placebo-hcplive 2024-11-20T16:57:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levi-04-improved-outcomes-in-knee-osteoarthritis-compared-with-placebo-hcplive 2024-11-20T16:57:57+00:00 weekly 0.7 https://trial.medpath.com/news/pbc-treatment-livdelzi-shows-benefits-for-2-5-years-in-phase-3-trial 2024-11-20T16:55:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbc-treatment-livdelzi-shows-benefits-for-2-5-years-in-phase-3-trial 2024-11-20T16:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-drug-labeling-for-fludarabine-phosphate-in-cll-onclive 2024-11-20T16:40:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-drug-labeling-for-fludarabine-phosphate-in-cll-onclive 2024-11-20T16:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/new-eu-approvals-citeline 2024-11-20T16:40:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-eu-approvals-citeline 2024-11-20T16:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-hympavzi-for-hemophilia-a-or-b-receives-eu-approval-outsourcing-pharma-com 2024-11-20T16:40:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-s-hympavzi-for-hemophilia-a-or-b-receives-eu-approval-outsourcing-pharma-com 2024-11-20T16:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/eupraxia-s-diffuspheretm-technology-demonstrates-targeted-drug-release-while 2024-11-20T16:35:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eupraxia-s-diffuspheretm-technology-demonstrates-targeted-drug-release-while 2024-11-20T16:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/taho-pharma-begins-patient-dosing-in-us-phase-iii-trial-of-antithrombotic-oral-dissolving 2024-11-20T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taho-pharma-begins-patient-dosing-in-us-phase-iii-trial-of-antithrombotic-oral-dissolving 2024-11-20T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/news/an-inhaled-pi3kd-inhibitor-disclosed-by-chiesi-farmaceutici-suggests-the-target-is-unsuitable-for-managing-copd 2024-11-20T16:13:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-inhaled-pi3kd-inhibitor-disclosed-by-chiesi-farmaceutici-suggests-the-target-is-unsuitable-for-managing-copd 2024-11-20T16:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-begins-multicenter-study-to-address-health-disparities-in-structural-heart-disease-care 2024-11-20T16:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-begins-multicenter-study-to-address-health-disparities-in-structural-heart-disease-care 2024-11-20T16:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/jacksonville-university-partners-with-brooks-rehabilitation-and-other-universities-to-develop 2024-11-20T16:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacksonville-university-partners-with-brooks-rehabilitation-and-other-universities-to-develop 2024-11-20T16:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-biopharma-received-nmpa-approval-for-zorifertinib-tablets-zorifer-r-the-world-s-first 2024-11-20T16:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-biopharma-received-nmpa-approval-for-zorifertinib-tablets-zorifer-r-the-world-s-first 2024-11-20T16:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/reused-pacemakers-are-good-as-new-kratom-still-readily-available-nih-ai-matches 2024-11-20T16:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reused-pacemakers-are-good-as-new-kratom-still-readily-available-nih-ai-matches 2024-11-20T16:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-updates-fludarabine-labeling-under-project-renewal-initiative-targeted-oncology 2024-11-20T16:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-updates-fludarabine-labeling-under-project-renewal-initiative-targeted-oncology 2024-11-20T16:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/holding-pattern-awaiting-clarity-on-vir-biotechnology-s-potential-amid-promising-trials-and 2024-11-20T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/holding-pattern-awaiting-clarity-on-vir-biotechnology-s-potential-amid-promising-trials-and 2024-11-20T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-gene-therapy-advances-to-pivotal-trials-in-dmd-inside-precision-medicine 2024-11-20T15:58:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-gene-therapy-advances-to-pivotal-trials-in-dmd-inside-precision-medicine 2024-11-20T15:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/research-finds-dlbcl-patients-starting-treatment-immediately-face-worse-outcomes 2024-11-20T15:56:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-finds-dlbcl-patients-starting-treatment-immediately-face-worse-outcomes 2024-11-20T15:56:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ai-powered-ultrasound-software-for-cardiac-amyloidosis-detection 2024-11-20T15:50:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-ai-powered-ultrasound-software-for-cardiac-amyloidosis-detection 2024-11-20T15:50:37+00:00 weekly 0.7 https://trial.medpath.com/news/dr-forsyth-on-a-phase-1-study-evaluating-intrathecal-cdc1s-in-leptomeningeal-disease-onclive 2024-11-20T15:50:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-forsyth-on-a-phase-1-study-evaluating-intrathecal-cdc1s-in-leptomeningeal-disease-onclive 2024-11-20T15:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/mira-reveals-innovative-phase-i-iia-protocol-design-and-selection-of-clinical-trial-site 2024-11-20T15:39:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-reveals-innovative-phase-i-iia-protocol-design-and-selection-of-clinical-trial-site 2024-11-20T15:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/ezh2-enzyme-linked-to-drug-resistance-and-tumor-growth-in-prostate-cancer 2024-11-20T15:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ezh2-enzyme-linked-to-drug-resistance-and-tumor-growth-in-prostate-cancer 2024-11-20T15:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bimekizumab-in-hidradenitis-suppurativa 2024-11-20T15:20:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bimekizumab-in-hidradenitis-suppurativa 2024-11-20T15:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-wins-fda-nod-for-new-inpen-app-to-support-launch-with-simplera-cgm 2024-11-20T15:01:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-wins-fda-nod-for-new-inpen-app-to-support-launch-with-simplera-cgm 2024-11-20T15:01:59+00:00 weekly 0.7 https://trial.medpath.com/news/eu-regulators-said-no-to-alzheimer-s-drug-leqembi-now-they-re-saying-yes 2024-11-20T14:59:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-regulators-said-no-to-alzheimer-s-drug-leqembi-now-they-re-saying-yes 2024-11-20T14:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-ongoing-biospace 2024-11-20T14:54:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-ongoing-biospace 2024-11-20T14:54:49+00:00 weekly 0.7 https://trial.medpath.com/news/ultromics-obtains-breakthrough-device-fda-clearance-for-its-cardiac-amyloidosis-screening 2024-11-20T14:54:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultromics-obtains-breakthrough-device-fda-clearance-for-its-cardiac-amyloidosis-screening 2024-11-20T14:54:49+00:00 weekly 0.7 https://trial.medpath.com/news/newamsterdam-pharma-announces-positive-topline-data-from-pivotal-phase-3-tandem 2024-11-20T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newamsterdam-pharma-announces-positive-topline-data-from-pivotal-phase-3-tandem 2024-11-20T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-therapeutics-granted-orphan-drug-and-atmp-status-for-deramiocel-by-european 2024-11-20T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capricor-therapeutics-granted-orphan-drug-and-atmp-status-for-deramiocel-by-european 2024-11-20T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-fast-track-designations-to-stargardt-disease-therapy 2024-11-20T14:43:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-fast-track-designations-to-stargardt-disease-therapy 2024-11-20T14:43:03+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-s-deramiocel-gains-key-ema-designations-for-dmd-investing-com 2024-11-20T14:37:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capricor-s-deramiocel-gains-key-ema-designations-for-dmd-investing-com 2024-11-20T14:37:48+00:00 weekly 0.7 https://trial.medpath.com/news/sage-scraps-huntington-s-hopeful-after-disappointing-phase-ii-data-biospace 2024-11-20T14:31:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-scraps-huntington-s-hopeful-after-disappointing-phase-ii-data-biospace 2024-11-20T14:31:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bimekizumab-for-adults-with-hidradenitis-suppurativa-hcplive 2024-11-20T14:23:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bimekizumab-for-adults-with-hidradenitis-suppurativa-hcplive 2024-11-20T14:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bimekizumab-bkzx-as-treatment-for-hidradenitis-suppurativa 2024-11-20T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bimekizumab-bkzx-as-treatment-for-hidradenitis-suppurativa 2024-11-20T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-ongoing 2024-11-20T14:14:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-ongoing 2024-11-20T14:14:10+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-says-fda-clears-inpen-app-clearing-path-for-glucose-monitoring-system-launch 2024-11-20T14:14:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-says-fda-clears-inpen-app-clearing-path-for-glucose-monitoring-system-launch 2024-11-20T14:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:14:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:14:02+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:13:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-initiates-alisertib-in-cancer-trial-tipranks-com 2024-11-20T14:13:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-initiates-alisertib-in-cancer-trial-tipranks-com 2024-11-20T14:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/towards-a-precision-approach-to-anesthetic-analgesic-immunomodulation-in-cancer 2024-11-20T14:10:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/towards-a-precision-approach-to-anesthetic-analgesic-immunomodulation-in-cancer 2024-11-20T14:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-announces-nhci-is-enrolling-patients-for-phase-iii-tiger-pac-trial-tipranks 2024-11-20T14:09:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renovorx-announces-nhci-is-enrolling-patients-for-phase-iii-tiger-pac-trial-tipranks 2024-11-20T14:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/study-unveils-key-strategies-against-drug-resistant-prostate-cancer-newsroom 2024-11-20T14:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-unveils-key-strategies-against-drug-resistant-prostate-cancer-newsroom 2024-11-20T14:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-s-bimzelx-approved-by-fda-for-treatment-of-adults-with-hidradenitis-suppurativa 2024-11-20T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-s-bimzelx-approved-by-fda-for-treatment-of-adults-with-hidradenitis-suppurativa 2024-11-20T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-therapeutics-granted-orphan-drug-and-atmp-status-globenewswire 2024-11-20T14:04:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capricor-therapeutics-granted-orphan-drug-and-atmp-status-globenewswire 2024-11-20T14:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/koelis-announces-the-first-interim-results-of-the-violette-globenewswire 2024-11-20T14:04:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/koelis-announces-the-first-interim-results-of-the-violette-globenewswire 2024-11-20T14:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/ultromics-obtains-breakthrough-device-fda-clearance-for-its-cardiac-amyloidosis-screening 2024-11-20T14:04:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultromics-obtains-breakthrough-device-fda-clearance-for-its-cardiac-amyloidosis-screening 2024-11-20T14:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotech-launches-phase-2-trial-for-advanced-breast-cancer-treatment-stock-titan 2024-11-20T14:03:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotech-launches-phase-2-trial-for-advanced-breast-cancer-treatment-stock-titan 2024-11-20T14:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-expands-phase-iii-pancreatic-cancer-trial-with-major-cancer-institute-partnership 2024-11-20T14:03:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renovorx-expands-phase-iii-pancreatic-cancer-trial-with-major-cancer-institute-partnership 2024-11-20T14:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-strategy-for-speeding-up-drug-approvals-in-the-eu-pharmaphorum 2024-11-20T14:03:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-strategy-for-speeding-up-drug-approvals-in-the-eu-pharmaphorum 2024-11-20T14:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/2024-a-breakthrough-year-for-hypoparathyroidism-treatment-labiotech 2024-11-20T14:02:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-a-breakthrough-year-for-hypoparathyroidism-treatment-labiotech 2024-11-20T14:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:01:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/new-details-on-a-risky-medical-device-show-need-for-more-fda-transparency-researchers-say 2024-11-20T14:01:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-details-on-a-risky-medical-device-show-need-for-more-fda-transparency-researchers-say 2024-11-20T14:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:00:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:00:27+00:00 weekly 0.7 https://trial.medpath.com/news/biovie-to-present-design-of-planned-phase-2-study-of-bezisterim-for-the-treatment-of-long 2024-11-20T13:55:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biovie-to-present-design-of-planned-phase-2-study-of-bezisterim-for-the-treatment-of-long 2024-11-20T13:55:06+00:00 weekly 0.7 https://trial.medpath.com/news/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-globenewswire 2024-11-20T13:47:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-globenewswire 2024-11-20T13:47:36+00:00 weekly 0.7 https://trial.medpath.com/news/precision-for-medicine-and-agena-bioscience-announce-strategic-partnership-yahoo-finance 2024-11-20T13:47:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-for-medicine-and-agena-bioscience-announce-strategic-partnership-yahoo-finance 2024-11-20T13:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-secures-fda-clearance-for-revolutionary-smart-insulin-dosing-system-mdt-stock-news 2024-11-20T13:43:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-secures-fda-clearance-for-revolutionary-smart-insulin-dosing-system-mdt-stock-news 2024-11-20T13:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/organovo-reports-positive-phase-2-results-for-liver-drug-fxr314-investing-com 2024-11-20T13:39:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/organovo-reports-positive-phase-2-results-for-liver-drug-fxr314-investing-com 2024-11-20T13:39:23+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-announces-topline-results-from-the-phase-2-dimension-study-of-biospace 2024-11-20T13:38:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-therapeutics-announces-topline-results-from-the-phase-2-dimension-study-of-biospace 2024-11-20T13:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-obesity-drug-reduces-risk-of-heart-failure-phase-iii-study-finds-medwatch 2024-11-20T13:36:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-obesity-drug-reduces-risk-of-heart-failure-phase-iii-study-finds-medwatch 2024-11-20T13:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-fda-clearance-for-new-inpentm-app-paving-the-way-for-its-smart-mdi 2024-11-20T13:35:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-fda-clearance-for-new-inpentm-app-paving-the-way-for-its-smart-mdi 2024-11-20T13:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/painreform-announces-initial-topline-data-for-prf-110-phase-3-clinical-trial 2024-11-20T13:34:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painreform-announces-initial-topline-data-for-prf-110-phase-3-clinical-trial 2024-11-20T13:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/painreform-announces-initial-topline-data-for-prf-110-phase-3-clinical-trial 2024-11-20T13:33:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painreform-announces-initial-topline-data-for-prf-110-phase-3-clinical-trial 2024-11-20T13:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full 2024-11-20T13:33:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full 2024-11-20T13:33:26+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-receives-orphan-medicinal-product-designation-from-ema-for-ocu410st 2024-11-20T13:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-receives-orphan-medicinal-product-designation-from-ema-for-ocu410st 2024-11-20T13:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-reports-fda-approval-of-bimzelx-in-moderate-to-severe-hidradenitis-suppurativa 2024-11-20T13:26:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-reports-fda-approval-of-bimzelx-in-moderate-to-severe-hidradenitis-suppurativa 2024-11-20T13:26:24+00:00 weekly 0.7 https://trial.medpath.com/news/november-20-2022-in-this-week-s-pct-grand-rounds-the-helix-pragmatic-trial-in 2024-11-20T13:23:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/november-20-2022-in-this-week-s-pct-grand-rounds-the-helix-pragmatic-trial-in 2024-11-20T13:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bimekizumab-for-adults-with-moderate-to-severe-hs-dermatology-times 2024-11-20T13:17:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bimekizumab-for-adults-with-moderate-to-severe-hs-dermatology-times 2024-11-20T13:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-releases-report-on-global-bladder-cancer-clinical-trials-offering-insights-for 2024-11-20T13:15:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-releases-report-on-global-bladder-cancer-clinical-trials-offering-insights-for 2024-11-20T13:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-data-inform-advancements-in-targeted-therapy-for-gastric-gej-cancers 2024-11-20T13:15:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-data-inform-advancements-in-targeted-therapy-for-gastric-gej-cancers 2024-11-20T13:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/melt-pharmaceuticals-reports-positive-phase-3-topline-efficacy-results-for-melt-300 2024-11-20T13:15:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melt-pharmaceuticals-reports-positive-phase-3-topline-efficacy-results-for-melt-300 2024-11-20T13:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/pharmanovia-licenses-lindis-catumaxomab-for-malignant-ascites-treatment 2024-11-20T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmanovia-licenses-lindis-catumaxomab-for-malignant-ascites-treatment 2024-11-20T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/mira-reveals-innovative-phase-i-iia-protocol-design-and-selection-of-clinical-trial-site 2024-11-20T13:06:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-reveals-innovative-phase-i-iia-protocol-design-and-selection-of-clinical-trial-site 2024-11-20T13:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/transitioning-active-clinical-trials-under-eu-ctr-contract-pharma 2024-11-20T13:06:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transitioning-active-clinical-trials-under-eu-ctr-contract-pharma 2024-11-20T13:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-way-to-run-clinical-trials-within-general-practice-reaches-1000-nhs-patients-recruited 2024-11-20T12:52:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-way-to-run-clinical-trials-within-general-practice-reaches-1000-nhs-patients-recruited 2024-11-20T12:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-s-bimzelx-granted-fda-approval-to-treat-hidradenitis-suppurativa-in-adults-pmlive 2024-11-20T12:40:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-s-bimzelx-granted-fda-approval-to-treat-hidradenitis-suppurativa-in-adults-pmlive 2024-11-20T12:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-announces-european-medicines-agency-grants-orphan-globenewswire 2024-11-20T12:40:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-announces-european-medicines-agency-grants-orphan-globenewswire 2024-11-20T12:40:14+00:00 weekly 0.7 https://trial.medpath.com/news/gigagen-commences-phase-i-clinical-trial-of-giga-2339-for-hepatitis-b-treatment 2024-11-20T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gigagen-commences-phase-i-clinical-trial-of-giga-2339-for-hepatitis-b-treatment 2024-11-20T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-bags-eu-okay-for-haemophilia-drug-hympavzi-pharmaphorum 2024-11-20T12:32:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-bags-eu-okay-for-haemophilia-drug-hympavzi-pharmaphorum 2024-11-20T12:32:58+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-s-eye-disease-drug-shows-84-lesion-reduction-receives-ema-orphan-status 2024-11-20T12:32:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-s-eye-disease-drug-shows-84-lesion-reduction-receives-ema-orphan-status 2024-11-20T12:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-clinical-trial-of-intranasal-dexmedetomidine-versus-inhaled-nitrous-oxide-for 2024-11-20T12:25:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-clinical-trial-of-intranasal-dexmedetomidine-versus-inhaled-nitrous-oxide-for 2024-11-20T12:25:25+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-gets-european-approval-of-hympavzi-hemophilia-drug-morningstar 2024-11-20T12:22:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-gets-european-approval-of-hympavzi-hemophilia-drug-morningstar 2024-11-20T12:22:47+00:00 weekly 0.7 https://trial.medpath.com/news/melt-pharma-s-melt-300-shows-breakthrough-results-in-phase-3-sedation-trial 2024-11-20T12:21:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melt-pharma-s-melt-300-shows-breakthrough-results-in-phase-3-sedation-trial 2024-11-20T12:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/melt-pharmaceuticals-reports-positive-phase-3-topline-efficacy-results-for-melt-300-its 2024-11-20T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melt-pharmaceuticals-reports-positive-phase-3-topline-efficacy-results-for-melt-300-its 2024-11-20T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-phase-iii-brooklyn-trial-safety-and-efficacy-of-obicetrapib-in-hefh-patients 2024-11-20T12:16:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-phase-iii-brooklyn-trial-safety-and-efficacy-of-obicetrapib-in-hefh-patients 2024-11-20T12:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/gigagen-commences-phase-i-clinical-trial-of-giga-2339-for-hepatitis-b-treatment 2024-11-20T12:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gigagen-commences-phase-i-clinical-trial-of-giga-2339-for-hepatitis-b-treatment 2024-11-20T12:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a 2024-11-20T12:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a 2024-11-20T12:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/injecting-hope-clinuvel-eyes-higher-scenesse-usage-in-europe-sharecafe 2024-11-20T12:01:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/injecting-hope-clinuvel-eyes-higher-scenesse-usage-in-europe-sharecafe 2024-11-20T12:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/sol-gel-announces-180-day-extension-to-regain-compliance-globenewswire 2024-11-20T12:01:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sol-gel-announces-180-day-extension-to-regain-compliance-globenewswire 2024-11-20T12:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-medicine-biomarkers-market-set-to-reach-79-26-billion-by-2034-driven-by-precision-oncology-and-ai 2024-11-20T11:52:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-medicine-biomarkers-market-set-to-reach-79-26-billion-by-2034-driven-by-precision-oncology-and-ai 2024-11-20T11:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/nih-developed-ai-algorithm-matches-potential-volunteers-to-clinical-trials-pharmabiz-com 2024-11-20T11:32:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-developed-ai-algorithm-matches-potential-volunteers-to-clinical-trials-pharmabiz-com 2024-11-20T11:32:30+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-phase-iii-brooklyn-trial-safety-and-efficacy-of-obicetrapib-in-hefh-patients 2024-11-20T11:16:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-phase-iii-brooklyn-trial-safety-and-efficacy-of-obicetrapib-in-hefh-patients 2024-11-20T11:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/rozebalamin-for-injection-25mg-mecobalamin-for-amyotrophic-lateral-sclerosis-launched-in-japan 2024-11-20T10:59:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rozebalamin-for-injection-25mg-mecobalamin-for-amyotrophic-lateral-sclerosis-launched-in-japan 2024-11-20T10:59:30+00:00 weekly 0.7 https://trial.medpath.com/news/msd-reports-topline-outcomes-from-phase-iii-nsclc-trial-of-pembrolizumab 2024-11-20T10:49:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-reports-topline-outcomes-from-phase-iii-nsclc-trial-of-pembrolizumab 2024-11-20T10:49:17+00:00 weekly 0.7 https://trial.medpath.com/news/sen-jam-pharma-launches-phase-ii-trial-of-hangover-prevention-treatment-msn 2024-11-20T10:41:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sen-jam-pharma-launches-phase-ii-trial-of-hangover-prevention-treatment-msn 2024-11-20T10:41:27+00:00 weekly 0.7 https://trial.medpath.com/news/msd-reports-topline-outcomes-from-phase-iii-nsclc-trial-of-pembrolizumab-yahoo 2024-11-20T10:33:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-reports-topline-outcomes-from-phase-iii-nsclc-trial-of-pembrolizumab-yahoo 2024-11-20T10:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-semaglutide-tops-madrigal-s-rezdiffra-in-nash-citeline 2024-11-20T10:25:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-s-semaglutide-tops-madrigal-s-rezdiffra-in-nash-citeline 2024-11-20T10:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/spyglass-pharma-completes-enrollment-in-phase-i-ii-study-of-its-promising-long-term 2024-11-20T09:40:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spyglass-pharma-completes-enrollment-in-phase-i-ii-study-of-its-promising-long-term 2024-11-20T09:40:16+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-gets-fda-approval-for-bimzelx-for-hidradenitis-suppurativa-bloomberg-law-news 2024-11-20T09:21:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-gets-fda-approval-for-bimzelx-for-hidradenitis-suppurativa-bloomberg-law-news 2024-11-20T09:21:46+00:00 weekly 0.7 https://trial.medpath.com/news/sen-jam-s-first-in-class-fda-regulated-hangover-cure-enters-phase-2-trials 2024-11-20T09:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sen-jam-s-first-in-class-fda-regulated-hangover-cure-enters-phase-2-trials 2024-11-20T09:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/lupus-therapeutics-statement-on-phase-3-phoenycs-go-positive-data-in-moderate-to 2024-11-20T08:57:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupus-therapeutics-statement-on-phase-3-phoenycs-go-positive-data-in-moderate-to 2024-11-20T08:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/regen-biopharma-inc-expands-vision-for-phase-1-clinical-trial-of-hemaxellerate 2024-11-20T08:47:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regen-biopharma-inc-expands-vision-for-phase-1-clinical-trial-of-hemaxellerate 2024-11-20T08:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/ongoing-and-planned-research-build-on-prior-advancements-in-er-her2-breast-cancer 2024-11-20T08:10:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ongoing-and-planned-research-build-on-prior-advancements-in-er-her2-breast-cancer 2024-11-20T08:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-shares-additional-draft-guidance-on-cgts-clinical-trials-arena 2024-11-20T08:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-shares-additional-draft-guidance-on-cgts-clinical-trials-arena 2024-11-20T08:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a-and 2024-11-20T08:03:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a-and 2024-11-20T08:03:29+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-sinks-on-setback-for-drugs-acquired-in-750m-buyout-biopharma-dive 2024-11-20T07:41:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyte-sinks-on-setback-for-drugs-acquired-in-750m-buyout-biopharma-dive 2024-11-20T07:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-us-fda-approval-for-generic-adderall-xr-extended-release-capsules 2024-11-20T07:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-receives-us-fda-approval-for-generic-adderall-xr-extended-release-capsules 2024-11-20T07:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-s-750m-escient-bet-flops-as-skin-disease-assets-stumble-biospace 2024-11-20T06:56:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyte-s-750m-escient-bet-flops-as-skin-disease-assets-stumble-biospace 2024-11-20T06:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/menstrual-regulation-and-promoting-pregnancy-acupuncture-method-based-jmdh 2024-11-20T06:41:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/menstrual-regulation-and-promoting-pregnancy-acupuncture-method-based-jmdh 2024-11-20T06:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a-and 2024-11-20T06:01:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a-and 2024-11-20T06:01:25+00:00 weekly 0.7 https://trial.medpath.com/news/ai-drug-repurposing-tool-offers-suggestions-based-on-disease-networks 2024-11-20T06:00:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-drug-repurposing-tool-offers-suggestions-based-on-disease-networks 2024-11-20T06:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-access-and-value-critical-analysis-reveals-geographic-disparities-and-questions-patient-benefits 2024-11-20T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-access-and-value-critical-analysis-reveals-geographic-disparities-and-questions-patient-benefits 2024-11-20T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/successful-completion-of-planned-idmc-review-of-action3-phase-3-fsgs 2024-11-20T05:49:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/successful-completion-of-planned-idmc-review-of-action3-phase-3-fsgs 2024-11-20T05:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-pipelinereview 2024-11-20T05:46:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-pipelinereview 2024-11-20T05:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase 2024-11-20T05:41:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase 2024-11-20T05:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-usfda-approval-for-mixed-salts-of-a-single-entity-amphetamine-er-capsules 2024-11-20T05:24:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-receives-usfda-approval-for-mixed-salts-of-a-single-entity-amphetamine-er-capsules 2024-11-20T05:24:32+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-companies-boost-medical-affairs-investment-to-enhance-clinical-trial-efficiency 2024-11-20T05:17:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-companies-boost-medical-affairs-investment-to-enhance-clinical-trial-efficiency 2024-11-20T05:17:48+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-results-from-glisten-phase-iii-trial-of-linerixibat-in-adults-with 2024-11-20T04:31:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-positive-results-from-glisten-phase-iii-trial-of-linerixibat-in-adults-with 2024-11-20T04:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-s-breakthrough-psychedelic-depression-drug-cyb003-sustains-12-month-symptom 2024-11-20T03:35:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-s-breakthrough-psychedelic-depression-drug-cyb003-sustains-12-month-symptom 2024-11-20T03:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-plots-regulatory-filings-for-pbc-itch-after-positive-phase-3-readout-endpoints-news 2024-11-20T03:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-plots-regulatory-filings-for-pbc-itch-after-positive-phase-3-readout-endpoints-news 2024-11-20T03:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-ziihera-zanidatamab-hrii-for-the-treatment-of-her2-positive-biliary-tract-cancer 2024-11-20T02:11:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-ziihera-zanidatamab-hrii-for-the-treatment-of-her2-positive-biliary-tract-cancer 2024-11-20T02:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/bimekizumab-data-from-acr-conference-highlights-sustained-efficacy-in-psoriatic-arthritis 2024-11-20T02:05:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bimekizumab-data-from-acr-conference-highlights-sustained-efficacy-in-psoriatic-arthritis 2024-11-20T02:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-wins-european-approval-for-ophthalmic-biosimilar-opuviz-maeilgyeongje 2024-11-20T02:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-wins-european-approval-for-ophthalmic-biosimilar-opuviz-maeilgyeongje 2024-11-20T02:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-reports-serious-adverse-event-in-phase-1-2-rett-study-of-gene-therapy-ngn-401 2024-11-20T02:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurogene-reports-serious-adverse-event-in-phase-1-2-rett-study-of-gene-therapy-ngn-401 2024-11-20T02:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-therapy-shows-promising-long-term-results-for-depression-the-streetwise-reports 2024-11-20T01:26:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-therapy-shows-promising-long-term-results-for-depression-the-streetwise-reports 2024-11-20T01:26:02+00:00 weekly 0.7 https://trial.medpath.com/news/epigenic-therapeutics-to-enter-clinical-development-of-epi-003-a-first-in-class-epigenetic 2024-11-20T01:15:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epigenic-therapeutics-to-enter-clinical-development-of-epi-003-a-first-in-class-epigenetic 2024-11-20T01:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-receives-u-s-fda-approval-for-bimzelx-bimekizumab-bkzx-as-the-first-il-17a-and-il-17f-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-11-20T01:11:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-receives-u-s-fda-approval-for-bimzelx-bimekizumab-bkzx-as-the-first-il-17a-and-il-17f-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-11-20T01:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/cardio-drugs-and-dementia-fampridine-and-working-memory-alzheimer-s-and-cancer 2024-11-20T00:45:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardio-drugs-and-dementia-fampridine-and-working-memory-alzheimer-s-and-cancer 2024-11-20T00:45:54+00:00 weekly 0.7 https://trial.medpath.com/news/cannabidiol-cbd-for-the-management-of-cannabis-withdrawal-unsw-sydney 2024-11-20T00:42:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cannabidiol-cbd-for-the-management-of-cannabis-withdrawal-unsw-sydney 2024-11-20T00:42:50+00:00 weekly 0.7 https://trial.medpath.com/news/essence-phase-3-trial-results-demonstrating-statistically-significant-and-superior-biospace 2024-11-20T00:37:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essence-phase-3-trial-results-demonstrating-statistically-significant-and-superior-biospace 2024-11-20T00:37:22+00:00 weekly 0.7 https://trial.medpath.com/news/cf-foundation-invests-15m-in-recode-therapeutics-to-boost-cf-gene-editing 2024-11-20T00:31:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cf-foundation-invests-15m-in-recode-therapeutics-to-boost-cf-gene-editing 2024-11-20T00:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-andexxa-could-be-headed-for-withdrawal-after-us-fda-s-negative 2024-11-20T00:21:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-andexxa-could-be-headed-for-withdrawal-after-us-fda-s-negative 2024-11-20T00:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-innovation-zasocitinib-s-journey-to-precision-inhibition-dermatology-times 2024-11-20T00:15:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-innovation-zasocitinib-s-journey-to-precision-inhibition-dermatology-times 2024-11-20T00:15:28+00:00 weekly 0.7 https://trial.medpath.com/news/und-research-team-approved-for-pediatric-eye-disease-group-clinical-trials 2024-11-20T00:11:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/und-research-team-approved-for-pediatric-eye-disease-group-clinical-trials 2024-11-20T00:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-promising-data-and-strategic-developments-justify-buy-rating 2024-11-20T00:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-promising-data-and-strategic-developments-justify-buy-rating 2024-11-20T00:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-20T00:06:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-20T00:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaceuticals-volume-17-issue-11-november-2024 2024-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaceuticals-volume-17-issue-11-november-2024 2024-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cero-therapeutics-holdings-inc-sec-10-q-report-tradingview 2024-11-19T23:36:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cero-therapeutics-holdings-inc-sec-10-q-report-tradingview 2024-11-19T23:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/non-binding-guidance-clinical-trial-diversity-in-focus-lexology 2024-11-19T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-binding-guidance-clinical-trial-diversity-in-focus-lexology 2024-11-19T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/news/parexel-introduces-fda-expedited-designation-trends-for-advanced-therapies 2024-11-19T23:15:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parexel-introduces-fda-expedited-designation-trends-for-advanced-therapies 2024-11-19T23:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-expands-drug-discovery-alliance-with-two-more-flagship-startups-for-cancer-and-obesity-research 2024-11-19T22:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-expands-drug-discovery-alliance-with-two-more-flagship-startups-for-cancer-and-obesity-research 2024-11-19T22:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/university-hospitals-only-health-system-in-northeast-ohio-offering-fda-approved 2024-11-19T22:28:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-hospitals-only-health-system-in-northeast-ohio-offering-fda-approved 2024-11-19T22:28:33+00:00 weekly 0.7 https://trial.medpath.com/news/first-generic-propofol-injectable-emulsion-for-dogs-receives-fda-approval-dvm360 2024-11-19T22:24:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-generic-propofol-injectable-emulsion-for-dogs-receives-fda-approval-dvm360 2024-11-19T22:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significant-reduction-in-systemic-lupus-erythematosus-disease-activity 2024-11-19T22:11:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significant-reduction-in-systemic-lupus-erythematosus-disease-activity 2024-11-19T22:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-2-synapse-cmt-study-to-test-effects-of-nmd670-in-charcot-marie-tooth 2024-11-19T22:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-phase-2-synapse-cmt-study-to-test-effects-of-nmd670-in-charcot-marie-tooth 2024-11-19T22:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primary-endpoints 2024-11-19T22:11:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primary-endpoints 2024-11-19T22:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-3-results-announced-for-jnj-2113-treatment-of-psoriasis-hcplive 2024-11-19T22:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-3-results-announced-for-jnj-2113-treatment-of-psoriasis-hcplive 2024-11-19T22:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/lly-oral-cholesterol-drug-lowers-lipoprotein-levels-in-phase-ii-study-yahoo-finance 2024-11-19T21:54:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lly-oral-cholesterol-drug-lowers-lipoprotein-levels-in-phase-ii-study-yahoo-finance 2024-11-19T21:54:02+00:00 weekly 0.7 https://trial.medpath.com/news/all-in-the-blood-new-way-to-detect-drug-resistance-in-ovarian-cancer-patients-biomelbourne-network 2024-11-19T21:53:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-in-the-blood-new-way-to-detect-drug-resistance-in-ovarian-cancer-patients-biomelbourne-network 2024-11-19T21:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/abk-biomedical-announces-fda-ide-stage-2-approval-for-route90-a-prospective-multi 2024-11-19T21:51:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abk-biomedical-announces-fda-ide-stage-2-approval-for-route90-a-prospective-multi 2024-11-19T21:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/ai-to-spot-aria-fda-says-yes-alzforum 2024-11-19T21:49:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-to-spot-aria-fda-says-yes-alzforum 2024-11-19T21:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-19T21:46:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-19T21:46:37+00:00 weekly 0.7 https://trial.medpath.com/news/pharmather-announces-update-on-fda-new-drug-application-for-ketamine-biospace 2024-11-19T21:41:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmather-announces-update-on-fda-new-drug-application-for-ketamine-biospace 2024-11-19T21:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/quralis-anqur-clinical-trial-of-qrl-201-in-als-advances-to-dose-range-finding-drf 2024-11-19T21:41:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quralis-anqur-clinical-trial-of-qrl-201-in-als-advances-to-dose-range-finding-drf 2024-11-19T21:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/sangamo-s-novel-gene-therapy-for-chronic-pain-gets-fda-clearance-for-clinical-trials 2024-11-19T21:25:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sangamo-s-novel-gene-therapy-for-chronic-pain-gets-fda-clearance-for-clinical-trials 2024-11-19T21:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-says-no-to-astellas-geographic-atrophy-drug-pharmaphorum 2024-11-19T21:23:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-says-no-to-astellas-geographic-atrophy-drug-pharmaphorum 2024-11-19T21:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-decentralized-clinical-trials-with-fda-s-guidance-law360 2024-11-19T21:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-decentralized-clinical-trials-with-fda-s-guidance-law360 2024-11-19T21:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/regen-biopharma-inc-expands-vision-for-phase-1-clinical-trial-of-hemaxellerate 2024-11-19T21:16:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regen-biopharma-inc-expands-vision-for-phase-1-clinical-trial-of-hemaxellerate 2024-11-19T21:16:44+00:00 weekly 0.7 https://trial.medpath.com/news/lindis-biotech-partners-with-pharmanovia-for-catumaxomab-launch-webdisclosure 2024-11-19T21:12:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lindis-biotech-partners-with-pharmanovia-for-catumaxomab-launch-webdisclosure 2024-11-19T21:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-19T21:11:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-19T21:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/cardiovascular-researchers-dramatically-reduce-size-and-severity-of-stroke-using-antidiabetic-drug-in-preclinical-models 2024-11-19T21:11:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiovascular-researchers-dramatically-reduce-size-and-severity-of-stroke-using-antidiabetic-drug-in-preclinical-models 2024-11-19T21:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-reports-positive-amplatzer-amulet-data-in-head-to-head-trial-with-boston-scientific-s-watchman 2024-11-19T21:05:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-reports-positive-amplatzer-amulet-data-in-head-to-head-trial-with-boston-scientific-s-watchman 2024-11-19T21:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/new-path-for-a-gene-therapy-trial-at-nih-for-a-rare-metabolic-disease 2024-11-19T20:50:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-path-for-a-gene-therapy-trial-at-nih-for-a-rare-metabolic-disease 2024-11-19T20:50:37+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-opinion-for-marketing-authorisation-of-aflibercept-biosimilar-fyb203 2024-11-19T20:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-issues-positive-opinion-for-marketing-authorisation-of-aflibercept-biosimilar-fyb203 2024-11-19T20:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/endoquest-robotics-applies-for-fda-approval-for-its-new-robotic-surgery-device 2024-11-19T20:46:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endoquest-robotics-applies-for-fda-approval-for-its-new-robotic-surgery-device 2024-11-19T20:46:12+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-trial-for-adicet-s-t-cell-therapy-adi-100-in-autoimmune-disease 2024-11-19T20:43:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-trial-for-adicet-s-t-cell-therapy-adi-100-in-autoimmune-disease 2024-11-19T20:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/the-liver-meeting-2024-bausch-health-presents-phase-3-study-design-for-investigational 2024-11-19T20:31:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-liver-meeting-2024-bausch-health-presents-phase-3-study-design-for-investigational 2024-11-19T20:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/uvax-bio-announces-interim-results-from-a-phase-1-clinical-trial-evaluating-its-hiv-1-vaccine 2024-11-19T20:29:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uvax-bio-announces-interim-results-from-a-phase-1-clinical-trial-evaluating-its-hiv-1-vaccine 2024-11-19T20:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-phase-3-study-of-subcutaneous-keytruda-to-treat-nsclc-meets-primary-goals 2024-11-19T20:26:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-phase-3-study-of-subcutaneous-keytruda-to-treat-nsclc-meets-primary-goals 2024-11-19T20:26:36+00:00 weekly 0.7 https://trial.medpath.com/news/driving-efficiency-and-roi-in-clinical-trials 2024-11-19T20:20:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/driving-efficiency-and-roi-in-clinical-trials 2024-11-19T20:20:59+00:00 weekly 0.7 https://trial.medpath.com/news/ale-p02-gains-fda-fast-track-status-in-cldn1-solid-tumors-targeted-oncology 2024-11-19T20:19:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ale-p02-gains-fda-fast-track-status-in-cldn1-solid-tumors-targeted-oncology 2024-11-19T20:19:43+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-arise-trial-of-parkinson-therapy-solengepras-begins-dosing-neurology-live 2024-11-19T20:06:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-arise-trial-of-parkinson-therapy-solengepras-begins-dosing-neurology-live 2024-11-19T20:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/jnj-2113-shows-promising-phase-3-results-for-plaque-psoriasis-dermatology-times 2024-11-19T20:06:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jnj-2113-shows-promising-phase-3-results-for-plaque-psoriasis-dermatology-times 2024-11-19T20:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/head-to-head-trial-to-compare-64cu-sar-bispsma-and-68ga-psma-11-pet-ct 2024-11-19T20:03:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/head-to-head-trial-to-compare-64cu-sar-bispsma-and-68ga-psma-11-pet-ct 2024-11-19T20:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/non-binding-guidance-clinical-trial-diversity-in-focus-insights-ropes-gray-llp 2024-11-19T20:02:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-binding-guidance-clinical-trial-diversity-in-focus-insights-ropes-gray-llp 2024-11-19T20:02:59+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-for-potentially-deadly-graft-versus-host-disease-science-x 2024-11-19T20:01:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-for-potentially-deadly-graft-versus-host-disease-science-x 2024-11-19T20:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/nih-develops-ai-algorithm-to-streamline-clinical-trial-matching-massdevice 2024-11-19T19:45:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-develops-ai-algorithm-to-streamline-clinical-trial-matching-massdevice 2024-11-19T19:45:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-crl-to-astellas-supplemental-new-drug-application-for-avacincaptad-pegol 2024-11-19T19:39:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-crl-to-astellas-supplemental-new-drug-application-for-avacincaptad-pegol 2024-11-19T19:39:36+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for 2024-11-19T19:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for 2024-11-19T19:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/covid-could-cure-cancer-researchers-make-astonishing-discovery-in-tumour-regression 2024-11-19T19:09:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-could-cure-cancer-researchers-make-astonishing-discovery-in-tumour-regression 2024-11-19T19:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/an-understudied-dementia-soon-to-get-a-pair-of-phase-ii-readouts-biocentury 2024-11-19T18:59:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-understudied-dementia-soon-to-get-a-pair-of-phase-ii-readouts-biocentury 2024-11-19T18:59:06+00:00 weekly 0.7 https://trial.medpath.com/news/publication-of-positive-phase-ii-clinical-data-for-fg001-in-patients-with-head-and-neck-cancer 2024-11-19T18:48:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/publication-of-positive-phase-ii-clinical-data-for-fg001-in-patients-with-head-and-neck-cancer 2024-11-19T18:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-car-t-cell-therapy-for-refractory-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-19T18:44:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-car-t-cell-therapy-for-refractory-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-19T18:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-announces-first-patient-dosed-in-japan-for-the-expansion-cohort-in-biospace 2024-11-19T18:34:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantern-pharma-announces-first-patient-dosed-in-japan-for-the-expansion-cohort-in-biospace 2024-11-19T18:34:29+00:00 weekly 0.7